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ABSTRACT
Study Purpose: Ovarian cancer, the most lethal gynecologic cancer, has had a relatively stable
mortality rate since 1975, despite a decrease in mortality for all gynecologic cancers combined.
Standard-of-care advances are needed to reduce ovarian cancer morbidity and mortality.
Advances must, however, undergo a long, rigorously controlled research process that can take
more than ten years before becoming available to the public. Further, few women with
persistent or recurrent ovarian cancer are offered or enrolled in the clinical trials that do exist at
select sites throughout the nation. The purpose of this multiple-case study is to identify
necessary and/or sufficient factors associated with enrollment in ovarian cancer clinical trials,
and to identify facilitators and barriers within the practice setting that, in the longer term, can be
used to inform targeted interventions to improve trial access and accrual. The multilevel factors
that were explored were aligned with the Consolidated Framework for Intervention Research
(CFIR). The study sought to answer two research questions. (1) Based on Qualitative
Comparative Analysis [QCA (Ragin, 1989)], what necessary and/or sufficient factors would
enable a woman with recurrent or persistent ovarian cancer to enroll in a clinical trial in Florida?
(2) What barriers and facilitators, practitioner and patient-specific, exist with regard to enrolling
women with ovarian cancer in clinical trials?
Materials and Methods: This multiple case study used online surveys to obtain quantitative and
qualitative data from two populations: women with ovarian cancer and nurses at various
referring practice sites. Data from Moffitt Cancer Center’s Total Cancer Care protocol was
requested to conduct chart reviews that would identify prospective participants. Qualitative
comparative analysis (QCA), which is useful for determining causality in small sample sizes,
was used to determine necessary and/or sufficient factors associated with enrollment by women
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with ovarian cancer in clinical trials, as well as barriers and facilitators related to clinical trial
enrollment.
Results: Women with ovarian cancer who participated in clinical trials were stage III/IV, wanted
information, and engaged in discussion about clinical trials, making those factors necessary for
enrollment in a study. Facilitators for participation were discussion with the provider of care, to
some extent the existence of patient-accessible clinical trial literature in the practice, knowledge
that health insurance covers standard of care costs, and having a provider who offers clinical
trials. Absence of those factors thus constitutes a barrier. For nurses, the impact of having a
practice team plan was related to enrolling women with ovarian cancer in clinical trials, and
feeling informed and comfortable with questions women might ask about trials.
Conclusion: Clinical trials are an underutilized priority for improving the standard of care and
reducing the high rate of morbidity and mortality associated with ovarian cancer. The data show
deficits and needs within two key interrelated populations: medical oncology practice nurses and
women with ovarian cancer. Opportunities exist within each level of the Consolidated
Framework for Implementation Research (CFIR); interviews should be used to confirm the
findings, which can be used to establish an interventional protocol to increase clinical trial
enrollment by women with ovarian cancer.
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CHAPTER ONE: INTRODUCTION
Statement of the Problem
Ovarian cancer led to 14,180 deaths and 21,290 new diagnoses in 2015 (ACS, 2015).
Ovarian cancer has had a relatively stable mortality rate since 1975 (NCI, 2013), despite a
decrease in mortality for all gynecologic cancers combined. Ovarian cancer, the most lethal
gynecologic cancer, has a disproportionately high ratio of deaths to initial diagnoses when
compared to other gynecologic cancers, as shown in Table 2.1 on page 7 (ACS, 2005a, 2009,
2013b). Ovarian cancer is usually diagnosed late in the course of the disease (stages III/IV)
(Hansen et al., 1993) because (1) its subtle symptoms mimic other conditions (Smith et al.,
2005), (2) its low incidence compared to many other cancers makes it a rare cancer (ACS,
2013b), (3) it should be but usually is not diagnosed, staged and initially treated by a
gynecologic oncologist, who is specially trained and able to provide the quality standard of care
(Goff, Matthews, et al., 2011; Goff, Miller, et al., 2011), (4) a screening test with sufficient
sensitivity and specificity has yet to be achieved (Goff, 2012), and (5) few women with persistent
or recurrent ovarian cancer are offered or enrolled in clinical trials (Morgan et al., 2013), despite
the National Comprehensive Cancer Network (NCCN) guideline that women with persistent or
recurrent ovarian cancer should be offered a clinical trial as a treatment option along with the
standard-of-care (SOC) regimen.
Need for the Study
SOC advances, for preceding reasons, are needed to reduce ovarian cancer morbidity
and mortality. Advances must, however, undergo a long, rigorously controlled research process
that is regulated by the U.S. Food and Drug Administration (FDA) that can take more than ten
years before becoming available to the public (FDA, 2012). The ovarian cancer SOC is
1

changing quickly, with evolving strategies being tested in clinical trials for their impact on overall
and progression-free survival and quality of life. Strategies include the use of neoadjuvant
therapy in advanced ovarian cancer, the use of biologic drugs that target specific gene
pathways, the impact of various dose densities and delivery routes (intraperitoneal and/or
intravenous), and the role of antiangiogenic drugs and maintenance therapies (Goff, 2013).
Participation in cancer clinical trials by adults with even the most common cancers is
well below 10 percent (Murthy, Krumholz, & Gross, 2004). Most studies that have been done
have focused on barriers and facilitators identified in groups of patients comprised of men and
women of wide-ranging age with various cancers (Comis, 2000; Comis, Miller, Aldige, Krebs, &
Stoval, 2003), or persons who responded to surveys that may never have had a diagnosis of
cancer (Gullo, 2005b; Taylor & Leitman, 2002). Some studies have focused on institutional
barriers (Dilts & Sandler, 2006), but few have looked at trial enrollment barriers within a system
linked to one type of subspecialty within a specific region, in the context of one type of cancer
that is particularly deadly.
Purpose of the Study
The purpose of this multiple-case study is to identify necessary and/or sufficient factors
associated with enrolling in clinical trials by women with persistent or recurrent ovarian cancer
throughout the state of Florida, and to identify facilitators and barriers within the gynecologic
oncology practice setting that, in the longer term, can be used to inform targeted interventions to
improve trial access and accrual. It is believed that the following research questions will help
fulfill the purpose of the study.
Research Questions
1. Based on Qualitative Comparative Analysis [QCA (Ragin, 1989)], what
necessary and/or sufficient factors enable a woman with recurrent or persistent
ovarian cancer to enroll in a clinical trial in Florida?
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2. What barriers and facilitators, practitioner and patient-specific, exist with regard
to enrolling women with ovarian cancer in clinical trials?
Overview of the Study
The theoretical framework for this study is the Consolidated Framework for
Implementation Research (CFIR), which is explained in chapter two. The study populations are
nurses in gynecologic or medical oncology practices, and women with ovarian cancer, identified
via Moffitt’s Total Cancer Care clinical and biospecimen repository. The TCC data was used to
conduct chart reviews to identify 60 community- and hospital-based practices, comprised of 30
gynecologic oncology and 30 medical oncology practices. Both study populations were
surveyed, and questions included demographics and factors for dimensions of the CFIR
theoretical model. Analysis of responses comprised descriptive statistics and Qualitative
Comparative Analysis (QCA), explained in chapter three.
Assumptions
Ovarian cancer is the deadliest of gynecologic cancers with a mortality rate that has
been stable for more than three decades, the details of which are explained in chapter one.
Despite rapid advances that are changing the standard of care to increase overall and
progression-free survival and quality of life, ovarian cancer diagnoses are still made at
advanced stages, when the disease usually will be terminal. Curative and prevention-focused
ovarian cancer clinical trials, therefore, remain a priority. The standard of care can improve only
via the clinical trial process, and yet the rarity of ovarian cancer makes adequate accrual
numbers for statistical power difficult to achieve. It is thus especially important that regional,
statewide, and national accrual-promoting network strategies be developed and shared to
increase opportunities for women with advanced disease to enroll in clinical trials.
Significance
This multiple case study attempted to identify necessary and/or sufficient factors related
to enrolling women with ovarian cancer in clinical trials. The surveys blended demographics,
3

quantitative and qualitative data to blend information that would not only detect barriers and
facilitators in practice settings, but also provide perceptions associated with conditions,
intentions, and behaviors. Detection of specific barriers and facilitators, along with explanations,
can guide further exploration for informed interventions to improve practice patterns and lay
perceptions with regard to clinical trial enrollment for women with persistent or recurrent ovarian
cancer. Subsequent intervention-focused research that strengthens ovarian cancer clinical trial
networks can be used to establish a model with guidelines that can be followed statewide and
beyond.
Organization of Dissertation Proposal
Chapter one is an introduction to the problem and the need for the study. Chapter two is
a literature review, describing the magnitude of the burden of ovarian cancer, as well as
associated challenges in reducing the morbidity and mortality associated with a disease that has
had a stable mortality rate for more than 30 years. Chapter two also discusses the theoretical
model in which the study is grounded. Chapter three focuses on the research methods and
analytic approach that was undertaken, explaining the research plan and research questions, as
well as the study populations, study schema, recruitment plan and proposed timeline. Chapter
four presents the results for the study populations, providing both descriptive statistics and QCA
results for women with ovarian cancer and nurses in gynecologic oncology and medical
oncology practices. Chapter five discusses the findings and their implications for public health
and practice, as well as the challenges, strengths and weaknesses associated with the study,
then concludes with recommendations.
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CHAPTER TWO: LITERATURE REVIEW
Background on Ovarian Cancer
Morbidity and Mortality
Ovarian cancer will lead to 14,180 deaths and 21,290 new diagnoses in 2015 (ACS, 2015).
Ovarian cancer has had a relatively stable mortality rate since 1975, as shown in Figure 2.1
(NCI, 2013), despite a decrease in mortality for all gynecologic cancers combined. Ovarian
cancer, the most lethal gynecologic cancer, has a disproportionately high ratio of deaths to initial
diagnoses when compared to other gynecologic cancers (see Table 2.1).
Nearly 90% of ovarian tumors arise from the epithelial cells on the surface of the ovary
(Fathalla, 1971; Rosen et al., 2009), and most are of the serous pathologic histotype, which is
classified as low grade or high grade on the basis of the extent of nuclear atypia and mitosis
(Malpica et al., 2004). Low- and high-grade ovarian cancers differ at the genomic and molecular
levels; low grade has less molecular abnormalities than high-grade carcinoma, which is more
aggressive and less responsive to standard-of-care treatment (Rosen et al., 2009).
Causes and Risks
Most epithelial ovarian cancers are diagnosed at advanced stages (III-IV), when the
disease is not likely to be curable (Hansen et al., 1993). Although the cause of ovarian cancer
is not known, several hereditary risk factors may be responsible for ovarian cancers in up to
10% of women: (1) having two or more first-degree relatives with ovarian cancer, (2) having a
positive BRCA1/2 genotype status, and (3) having a family history of hereditary nonpolyposis
colorectal cancer (HNPCC) (Finch et al., 2006; Fleming, Ronnett, & Seidman, 2009).

5

Figure 2.1. Age-Adjusted U.S. Mortality Rates by Cancer Site. All Ages, All Races, Female,
1975-2009
Table 2.1. Gynecologic cancer incidence, mortality, and ration of mortality to incidence
(ACS, 2005b, 2009, 2013b)
2005

2009

Site
Ovary
Vagina
Cervix
Vulva

Incidence
22,220
2,140
10,370
3,870

Mortality
16,210
810
3,710
870

Ratio of
deaths to
new
cases
0.73
0.38
0.36
0.22

Uterus

40,880

7,310

0.18

Incidence
21,550
2,160
11,270
3,580
42,160
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2013

Mortality
14,600
770
4,070
900

Ratio of
deaths
to new
cases
0.68
0.35
0.36
0.25

Incidence
22,240
2,890
12,340
4,700

Mortality
14,030
840
4,030
990

Ratio of
deaths
to new
cases
0.63
0.29
0.33
0.21

7,780

0.18

49,560

8,190

0.16

Risk is increased by nulliparity or being older than 35 years at first birth and possibly
having hormone therapy (Morch, Lokkegaard, Andreasen, Kruger-Kjaer, & Lidegaard, 2009).
Factors that may reduce risk include being 25 or younger at first birth and having used oral
contraceptives (Fleming et al., 2009). Age at first birth and use of oral contraceptives are
believed to affect risk because of their influence on the number of total lifetime ovulations and
exposure to estrogen (Kaga et al., 1996; Riman, Persson, & Nilsson, 1998; Rossouw et al.,
2002). Also believed to affect risk is breastfeeding, for its effect on reducing ovulations and thus
lessening continuous trauma to the epithelium (Fleming et al., 2009). That trauma, followed by
epithelial cell proliferation, has been suspected to promote mutations or carcinogenesis, a
hypothesis supported by studies that have correlated suppression of ovulation by oral
contraceptives and/or pregnancy with reduced risk of ovarian cancer (Casagrande et al., 1979;
Tung et al., 2005). Advances in cytogenetics, the study of human chromosomes and their
relation to disease, and histopathology, the tissue changes associated with disease, have led to
the knowledge that type I, low grade, generally means the patient will have a good prognosis,
and type II, high grade, tends to be aggressive and suggests a poor prognosis (Kurman,
Visvanathan, Roden, Wu, & Shih Ie, 2008). Gene expression profiling has reached from
research laboratories into the clinical practice setting, allowing thousands of genes to be
measured at one time to generate expression profiles that can be used to predict prognosis and
therapeutic strategies (Chon & Lancaster, 2011; Dressman et al., 2007; Lancaster et al., 2006).
Prevention and Screening
Because the precise cause of ovarian cancer is not known, even though some risk
factors have been identified, clear-cut guidelines for preventing ovarian cancer do not exist
(Petroff, 2012). The risk factors in the preceding section, however, suggest that certain
behaviors may moderate risk for acquiring ovarian cancer. Women with two or more firstdegree relatives who have been diagnosed with ovarian cancer can be tested for the BRCA1/2
or HNPCC gene mutation, and if the results are positive they may opt for more intensive
7

surveillance or prophylactic oophorectomy, removal of the ovaries (Whittemore, Harris, & Itnyre,
1992b). Hereditary gene mutations, however, account for only up to 10% of ovarian cancers
(Ramirez, Chon, & Apte, 2011; Whittemore, Harris, Itnyre, & Halpern, 1992).
A screening test with adequate sensitivity and specificity has yet to be developed, and
efforts to create a cost-effective screening test are hampered by lack of an in situ lesion, (Harris,
Whittemore, & Intyre, 1992), and diagnosis requires a major operative procedure (laparotomy or
laparoscopy) (Whittemore, Harris, & Itnyre, 1992a). Furthermore, screening should ensure that
early-detection benefits outweigh morbidity/mortality risk (Whittemore, Harris, Itnyre, et al.,
1992), which is impeded by the low incidence rate of ovarian cancer; for example, in women
over 50 there are 40 cases per 100,000 women (Horn-Ross, Whittemore, Harris, & Itnyre,
1992). Goff (2012) explained how low incidence impedes the development of a perfect
screening test, which would require 2,500 screens
… to detect 1 case of ovarian cancer.… if a screening test has only a 1% falsepositive rate (sensitivity of 99%), then of every 2,500 women screened 25 would
have false-positive tests yielding a positive predictive value (PPV) of 4%. … a
screening test that results in a major surgical procedure should have a PPV of at
least 10%. That means for every case of cancer detected there would be no
more than 10 “unnecessary” surgeries (false positives). With an incidence of 40
in 100,000, a screening test would need a specificity of 99.6% or a false-positive
rate of less than 0.4% to have a PPV of 10% or higher. … Because 2,500
women need to be screened to detect a single ovarian cancer, the cost must be
affordable, and the test readily available and acceptable to patients (p. 184).
In addition to low incidence, barriers to screening and prevention include difficulty in
visualizing early stage changes and the use of laparoscopic tissue sampling only for diagnostic
purposes, thus limiting the availability of tissue-based biomarkers for prevention trials (Petroff,
2012). In the absence of concrete data on ovarian cancer etiology, because breast and ovarian
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cancers share common risk factors, Petroff (2012) suggested that prevention should be pursued
by developing dual breast-ovarian cancer prevention guidelines. Commonalities between
breast and ovarian cancers include estrogen exposure, BRCA1/2 mutations, and suspected
lifestyle factors that include obesity, age at first childbirth, and age at menarche and menopause
(Brekelmans, 2003).
The Society of Gynecologic Oncologists (SGO) does not recommend use of two recently
developed biomarker assessment screening tools: (1) OVA1 (Vermillion, Inc., Austin, Texas),
that measures transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125 to
assess referrals for surgery, and (2) OvaSure (LabCorp, Burlington, North Carolina), that
assesses leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor,
and cancer antigen (CA) 125 (Whittemore, Harris, et al., 1992b).
The U.S. Preventive Services Task Force, based on evidence that annual transvaginal
ultrasonography and testing for the serum tumor marker CA-125 failed to reduce the number of
ovarian cancer deaths, recommends against ovarian cancer screening for women of average
risk (Harris et al., 1992). For women with a family history of ovarian cancer, genetic testing is
recommended, followed by counseling about whether to pursue frequent surveillance with or
without prophylactic oophorectomy (Force, 2005; Menon & Jacobs, 2001; Poovorawan et al.,
2011; Whittemore, Harris, Itnyre, et al., 1992)
Detection of Ovarian Cancer
According to the American College of Obstetrics and Gynecology (ACOG), the best way
to detect ovarian cancer is for both the patient and her physician to suspect the diagnosis
because she is symptomatic (Whittemore, Harris, et al., 1992a). SGO has stated that despite
the fact that most women with ovarian cancer have symptoms, they remain undiagnosed for
many months (Whittemore, Harris, Itnyre, et al., 1992).
Symptoms experienced prior to diagnosis, as revealed by a survey of 1,725 U.S. and
Canadian women with ovarian cancer included, in order of prevalence from greatest to least:
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increased abdominal size, bloating, fatigue, abdominal pain, indigestion, urinary frequency,
pelvic pain, constipation, back pain, pain with intercourse, inability to eat normally, palpable
mass, vaginal bleeding, weight loss, nausea, bleeding with intercourse, diarrhea, and deep vein
thrombosis; 5% of women experienced no symptoms (Horn-Ross et al., 1992). In Goff’s study
(2012), 89% of women with early stage disease had symptoms prior to being diagnosed, and
their symptoms did not differ from those experienced by women with advanced-stage disease.
No available test has been shown to detect ovarian cancer reliably, at an early, curable stage (III), thus to optimize the chance for a timely diagnosis, educating women and practitioners about
symptoms and prompt initiation of a diagnostic regimen is essential (Whittemore, Harris, et al.,
1992a; Whittemore, Harris, Itnyre, et al., 1992).
An ovarian cancer diagnosis is generally precipitated by a suspicious palpable pelvic
mass, ascites, and/or abdominal distention, accompanied by symptoms that may include
bloating, pain, difficulty eating, feeling full quickly, and having urinary symptoms of urgency or
frequency (Goff, Mandel, Muntz, & Melancon, 2000). The diagnostic protocol includes family
history, an abdominal/pelvic exam, gastrointestinal evaluation if clinically appropriate, ultrasound
and/or pelvic computed tomography (CT) scan, chest imaging, measure of CA-125, and
complete blood count and chemistry profile (Morgan et al., 2011; Morgan et al., 2013).
Staging and Treatment
Staging. The treatment plan is dictated by ovarian cancer staging, using a valid and
reliable evidence-based approach to cancer as classified by the International Federation of
Gynecology and Obstetrics (FIGO) staging system (Ness et al., 2002). Table 2.2 explains
ovarian cancer stages, for which FIGO established guidelines as early as 1973 (Ness et al.,
2002).
Surgery. The staging process requires removal of the ovaries, fallopian tubes, and
uterus, as well as extra-ovarian sites such as lymph nodes, peritoneum, and omentum, which
can harbor cancer cells (Schorge, Eisenhauer, & Chi, 2012). In 1994 the National Institutes of
10

Health (NIH) published guidelines on ovarian cancer treatment that made the complete staging
procedure the standard of care (NIH, 1994). A woman with a pelvic mass will receive
cytoreductive surgery, or debulking, for stages II, III, and IV for the purpose of removing as
much cancer as possible to promote drug delivery to smaller tumors with good blood supply,
remove drug resistant clones to reduce the likelihood of early drug resistance, and remove
tumors in locations that could lead to bowel obstruction (Schorge et al., 2012). Surgical
debulking is usually done by laparotomy or total abdominal hysterectomy, bilateral salpingooophorectomy with comprehensive staging (or unilateral salpingo-oophorectomy for stages 1A
to 1C) (Morgan et al., 2011; Morgan et al., 2013). Gynecologic surgeons attempt to remove all
Table 2.2. FIGO Staging for Ovarian Cancer, adapted from (Purdie, Bain, Siskind, Webb, &
Green, 2003)
Stage I
Ia
Ib
Ic
Stage II
IIa
IIb
IIc
Stage III
IIIa
IIIb
IIIc
Stage IV

Limited to ovaries
Limited to 1 ovary, no ascities with malignant cells; no tumor on surface; intact
capsule
Limited to both ovaries; no ascites with malignant cells; no tumor on surface;
intact capsules
Either 1a or 1b, but tumor on surface of one or both ovaries, or capsule ruptured,
or ascites with malignant cells or positive peritoneal washings
Involving 1 or both ovaries with pelvic extension
Extension and/or metastases to the uterus and/or tubes
Extension to other pelvic tissues
Either IIa or IIb, but tumor on surface of either or both ovaries, or with capsule)s_
ruptured, or with ascites containing malignant cells, or with positive peritoneal
washings.
Involving 1 or both ovaries with peritoneal implants outside the pelvis and/or
positive retroperitineal or inguinal nodes. Superficial liver metastases. Tumor is
limited to pelvis, but with malignant extension to small bowel or omentum.
Grossly limited to true pelvis, with negative nodes, but histologically confirmed
microscopic seeding of abdominal peritoneal surfaces, or histologic proven
extension to small bowel or mesentery.
Involves 1 or both ovaries with confirmed implants, peritoneal metastasis of
abdominal peritoneal surfaces, none greater than 2 cm in diameter; negative
nodes.
Peritoneal metastasis beyond pelvis greater than 2 cm in diameter and/or positive
retroperitoneal or inguinal nodes.
Involves 1 or both ovaries with distant metastases. If pleural effusion is present,
there must be positive cytology to allot a case to Stage IV. Parenchymal liver
metastasis equals Stage IV.
11

of the tumor, and if that is not possible, they try to leave no more than one centimeter in
diameter of tumor tissue, which is called optimal cytoreduction, versus suboptimal, indicating
more than a centimeter of residual disease (Ness & Cottreau, 1999). In the 10% of cases that
are diagnosed in women under 40, fertility-sparing surgery can be considered when cancer is
limited to one ovary, especially if it is low grade (Schorge et al., 2012). Multiple surgeries are
likely in women with advanced (stage III/IV) disease as tumors become chemoresistant and
recur.
Chemotherapy. Staging (see Figure 2.2, below), determination of histopathologic tumor
type, and disease history (recurrence and response to prior therapies) will guide the selection of
chemotherapeutic agents; neoadjuvant chemotherapy, using pre-operative tumor-reducing
chemotherapy, may be advised for bulky stage III/IV disease.

Stage IA or IB

Grade 1

Observe

Grade 2

Observe or
IV taxane/carboplatin 3-6 cycles

Grade 3
or clear
cell

IV taxane/carboplatin 3-6 cycles
IV taxane/carboplatin 3-6 cycles

Stage IC

• IP chemotherapy in optimally
debulked Stage II/III or
• IV taxane/carboplatin 6-8
cycles
• Completion surgery per
response & resectability
• Neoadjuvant bulky III/IV

Stage II, III, IV

Figure 2.2. Adjuvant/Primary (first-line) Chemotherapy by Stage (Adapted from Morgan, 2013)
Stage IA/IB. The current standard of care for stage IA/IB patients, if grade 1, following
surgery, is observation; if a woman’s ovarian cancer is grade 2, she may be observed or given 3
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to 6 cycles of an intravenous taxane with carboplatin; if grade 3, she will be advised to receive
the preceding chemotherapy (Morgan et al., 2013)
Stage IC. Stage IC, any grade, calls for 3 to 6 cycles of intravenous taxane/carboplatin.
Stages II - IV. Women who are stage II through IV may have intraperitoneal or
intravenous delivery of platinum-based therapy, perhaps with subsequent surgery, following
neoadjuvant chemotherapy, or secondary, tertiary, or palliative (Schorge et al., 2012).
Intraperitoneal delivery of chemotherapy, versus intravenous delivery, provides direct exposure
that has been shown to prolong overall and progression-free survival in advanced ovarian
cancer for up to 16 months (Kalaaji et al., 2012; Lalwani et al., 2011; Wenzel, Anderson, et al.,
2007).
Most women who are diagnosed at Stage III/IV and who respond to platinum-based
therapy will have recurrent disease, and some will become resistant to platinum therapy earlier
than others. As platinum resistance increases, additional cytotoxic drugs will be introduced,
among them docetaxel, gemcitabine, doxorubicin, etoposide, topotecan, cyclophosfamide,
capecitabine, ifosfamide, and oxaliplatin. In addition to cytotoxic drugs, hormonal therapies such
as anastrozole, letrozole, and tamoxifen may be effective, as well as targeted therapy with
bevacizumab, that inhibits vascular endothelial growth factor (VEGF) (Morgan et al., 2011;
Morgan et al., 2013). Notably, the National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines in Oncology (page 89) state that women with persistent or recurrent ovarian
cancer, which comprises most women with the disease, should be offered a clinical trial
(Morgan et al., 2011; Morgan et al., 2013).
Disparities
Ovarian cancer incidence is highest in white women (8.4 per 100,000), followed by black
women (6.7 per 100,000), Hispanic women (5.8 per 100,000), American Indian/Alaska Native
women (5.5 per 100,000), and Asian/Pacific Islander women (4.8 per 100,000 women) (NCI,
2013). Although a slight improvement in mortality occurred over the last 30 years, survival in
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black women is worse than that of white women (Nayak et al., 2011). The five-year survival rate
for white women improved from 37% to 45% between 1975 and 2004, but for black women it
decreased from 43% to 38% during the same time span (Jemal et al., 2009). In spite of
published guidelines, only 50% of U.S. women with ovarian cancer undergo the correct
procedure; most who were inaccurately staged in a study were poor, elderly, black or Hispanic
(Goff et al., 2007).
In a meta-analysis, Terplan and colleagues searched MEDLINE, PsychInfo, and
EMBASE for ovarian cancer studies that reported race for women who were treated in North
America (Terplan, Smith, & Temkin, 2009). The greatest advance in ovarian cancer survival
emerged with platinum-based chemotherapy in the 1980s, it is thus important to note that blackwhite survival disparities emerged after 1985. The researchers therefore suggest that blackwhite ovarian-cancer survival disparity may result from inequitable access to care (Terplan et
al., 2009).
A cross-sectional study of 13,858 women (891 black and 12,967 white) diagnosed with
epithelial ovarian cancer between 1981 and 2000, whose records were in the Florida Cancer
Data System (FCDS), revealed racial differences in patterns of care among women living in
Florida (Williams, Stockwell, Hoffman, & Barnholtz-Sloan, 2010). Black women diagnosed with
advanced disease were not as likely to receive chemotherapy, even though they were younger
on average than white women in the study, which, in light of the disparity that is discussed
below with regard to older women, raises a red flag on the impact of race on access to the
standard of care.
Women in lower income neighborhoods who were under/uninsured had worse outcomes
than women of better means because of limited options that force them to seek care at public
hospitals, where they are likely to receive substandard care without correct staging and
chemotherapy (Boyd, Novetsky, & Curtin, 2011; Chan et al., 2008). Women who live in rural
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and western regions have worse outcomes than women in metropolitan and eastern regions
who receive care from board-certified subspecialists (Riman et al., 1998).
In spite of published guidelines, only half of U.S. women with ovarian cancer undergo
the correct procedure; most who were inaccurately staged in a study were poor, elderly, black or
Hispanic (Goff et al., 2007). The disparity in Hispanic women may be greater than known; some
studies have excluded them because their numbers were too small in the populations of study
(Williams et al., 2010). Moreover, despite the guideline that women with persistent or recurrent
ovarian cancer should be offered a clinical trial as a treatment option, many women over 65,
regardless of their race/ethnicity, are not offered clinical trials because of preconceived notions
that older patients will be less compliant and prone to complications related to comorbidities
(Harter et al., 2005)
Impact of Ovarian Cancer on Quality of Life
Advanced ovarian cancer and its treatment are life-altering states of being with serious
physical, mental, and social consequences. Physical difficulties include recovery from major
abdominal surgery and side effects from platinum-taxane chemotherapy that include fatigue,
nausea, neurotoxicity, alopecia, neutropenia, myelosuppression, and stomatitis (Grzankowski &
Carney, 2011). Major surgery can lead to postoperative complications such as bleeding,
pulmonary emboli, wound or urinary tract infections, dehydration, and fluid/electrolyte
imbalances; upon healing, women face chemotherapies, either intravenously (IV) or
intraperitoneally (IP), whose side effects can include nausea, fatigue, and neuropathy
(Bohnenkamp, LeBaron, & Yoder, 2007a, 2007b). While IP therapy has been shown to improve
overall survival by nearly 16 months, a GOG study that compared IV and IP side effects found
the latter to be significantly greater and to include neurotoxicity and abdominal discomfort
(Wenzel, Huang, et al., 2007). Women being given palliative chemotherapy for terminal disease
expect that it will make them feel better, delay further problems, make them live longer, and
even cure their disease (Doyle, Crump, Pintilie, & Oza, 2001); unrealistic expectations may lead
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them to tolerate side effects that they would not normally accept if they had a more realistic
perspective of the limitations of palliative chemotherapy, perhaps helping them to transition into
hospice earlier, where quality of life is the priority.
Having advanced ovarian cancer with a poor prognosis can lead or often leads to anxiety

and depression (Grzankowski & Carney, 2011), and many women have significant stress as
they await tumor marker test results that are an ongoing part of surveillance (Parker et al.,
2006). Women whose subtle symptoms were presumed to be common gastrointestinal ailments
and were later diagnosed with advanced disease can harbor provider mistrust (Walker &
Robinson, 2009). Initial surgery is often driven by urgency related to increasing discomfort, and
women are often triaged to general surgeons. Upon learning the diagnosis postoperatively, a
patient’s mistrust may further be compounded by discovering a gynecologic oncologist is
specially trained for accurate staging, optimal cytoreduction, and intraperitoneal port placement,
all of which comprise life-extending ovarian-cancer standard-of-care procedures (Engelen et al.,
2006).
Social issues include strained interpersonal relations resulting from time constraints
imposed by medical visits, treatment and recovery. A couple’s intimacy can be compromised by
sexual dysfunction from fatigue, vaginal dryness from surgery-related nerve damage, anxiety,
depression, or negative body-image perceptions (Grzankowski & Carney, 2011). Women may
lose jobs because of illness-related absences, thus losing health insurance when they most
need it (Tunceli, Short, Moran, & Tunceli, 2009).
Gynecologic Oncologists, Targeted Therapies, and Clinical Trials
Inequitable Access to Gynecologic Oncologists
It is known that treatment for ovarian cancer by a gynecologic oncologist yields accurate
staging, optimal treatment according to national guidelines, the opportunity for a clinical trial,
and access to better outcomes and quality of life. Women treated by a gynecologic oncologist
had four times the probability of receiving recommended staging procedures compared to those
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not treated by a gynecologic oncologist (Cress et al., 2011). In a study of the U.S. distribution of
gynecologic oncologists that was sponsored by the Division of Cancer Prevention and Control
(DCPC) within the Centers for Disease Control (CDC) starting in 2008, the investigative team
reported at the 2011 annual meeting of the Society of Gynecologic Oncologists that more than
99% of gynecologic oncologists practice in metropolitan counties, thus few were found in
nonmetropolitan counties, and none were found in rural counties (Cooney et al., 2011). The
CDC ovarian-cancer workgroup has emphasized the need to find ways to better communicate
with and educate primary care doctors in referring women for follow-up diagnostic tests
(Newkirk, Biesinger, Chon, Yokomori, & Xie, 2011).
Awareness of Genomic Research for Improved Care Through Targeted Therapies
Genomics has opened the door to an exciting array of therapies that target specific
molecular pathways and have the potential to interfere with tumor growth and survival
(Lancaster et al., 2006). Genomic oncology holds promise for a major transformation in
oncology standards of care; emerging biologic therapies have the potential to moderate the use
of cytotoxic drugs, thus improving outcomes while diminishing side effects and toxicities
associated with traditional chemotherapies (Chon & Lancaster, 2011).
Awareness of and Access to Clinical Trials
The CDC has asserted the importance of collaborative efforts among federal agencies
and public health partners to identify resources to remove barriers to participation in clinical
trials by women with ovarian cancer (Trivers, Stewart, Peipins, Rim, & White, 2009). NCCN
guidelines assert that a clinical trial should be an option for women with persistent or recurrent
ovarian cancer (Morgan et al., 2011; Morgan et al., 2013). In spite of the direct relationship
between clinical trials and improved standards of care, a cross-sectional population-based
analysis of the NCI Clinical Trial Cooperative Group breast, colorectal, lung and prostate cancer
studies from 2000 to 2002 revealed that cancer trial enrollment was low for all patient groups,
with ethnic minorities, women, and the elderly less likely to enroll in cooperative group trials than
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whites, men, and younger patients (Murthy et al., 2004). Although participation in clinical trials
by all adults with cancer has been low historically, improved survival rates in women with
ovarian cancer have been linked to clinical trials (Chan et al., 2006).
Clinical Trial Process, Phases, Sponsors, and Protections
The lengthy process of developing new therapies, which can span 15 years from
preclinical bench to clinical trials to approval for use in patients, is rigorously managed and
overseen by the U.S. Food and Drug Administration (FDA). The steps in the approval process
are summarized in Table 2.3 (FDA, 2012).
Phase I, II, and III clinical trials test a drug or device sequentially (see Table 2.4).
Researchers may combine a study as a Phase I/II or II/III trial in one protocol, which aids a more
expedient transition between phases. Less commonly used are Phase 0 and IV studies. Phase
0 refers to extremely small studies to help a researcher determine whether a new agent should
be tested in a Phase I trial.

Table 2.3. Drug Review Steps Simplified (FDA, 2012)
1.
2.
3.
4.
5
6.
7.
8.
9.
10.
11.

Preclinical (animal) testing.
An investigational new drug application (IND) outlines what the sponsor of a new drug
proposes for human testing in clinical trials.
Phase 1 studies (typically involve 20 to 80 people).
Phase 2 studies (typically involve a few dozen to about 300 people).
Phase 3 studies (typically involve several hundred to about 3,000 people).
The pre-NDA period, just before a new drug application (NDA) is submitted. A common
time for the FDA and drug sponsors to meet.
Submission of an NDA is the formal step asking the FDA to consider a drug for marketing
approval.
After an NDA is received, the FDA has 60 days to decide whether to file it so it can be
reviewed.
If the FDA files the NDA, an FDA review team is assigned to evaluate the sponsor's
research on the drug's safety and effectiveness.
The FDA inspects the facilities where the drug will be manufactured as part of the approval
process.
FDA reviewers will approve the application or issue a complete response letter.

18

Phase IV trials monitor long-term safety and effectiveness and run after a new treatment
has been approved and is on the market (NCI, 2014).
Sponsors of Cancer Clinical Trials
Trial sponsors can be from private industry such as a pharmaceutical company, federal
agencies such as the National Cancer Institute or the Department of Defense, or private
nonprofit foundations who are advocates for education and research related to a specific
disease, for example the Ovarian Cancer Research Foundation (OCRF) (OCNA, 2014).
Human Subjects Protections and Regulatory Policies
Cancer clinical trial protocols are first approved by scientific experts that comprise
Scientific Review Committees (SRC) within a facility that offers a study, before being reviewed
by an institutional review board (IRB). When a study has been approved by the preceding
authorities, after it is launched it is monitored by the SRC and IRB, as well as an external Data
and Safety Monitoring Board (if a Phase III study), and by the research team and the actual trial
sponsor (NCI, 2012).

Table 2.4. Clinical Trials, Phases I, II, III Briefly Described. Adapted from (NCI, 2014)
Phase I

•
•

Phase II

•
•
•

Phase III

•

To find a safe dose
To decide how a new treatment should be given (orally,
intravenously, for example)
To see how the new treatment affects the human body
To determine if the new treatment affects a certain cancer
To see how the treatment affects the human body.
To compare the new treatment (or new use of an existing
treatment used in another way) with the current standard
treatment
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15 – 30
participants

Less than
100
participants
100 to
several
thousand

Key Persons Within the Practice Setting Involved in the Ovarian Cancer Clinical Trial
Enrollment Process.
The person with the greatest influence on a woman with ovarian cancer, in accordance
with what the literature on high patient regard for physician opinion, is the gynecologic
oncologist, who can raise awareness of and direct women in finding appropriate clinical trials.
Moreover, a portion of gynecologic oncologists may actually be principal investigators of clinical
trials. Also in a position to be influential in raising awareness and supporting women in finding
clinical trial resources are midlevel practitioners who see existing patients and monitor them
during surveillance, which puts them in a prime position to notice if serum CA125 levels appear
to be rising or other symptoms are emerging that may signal a possible recurrence. Outpatient
and inpatient nurses also spend time with their patients, perhaps more time than any other
provider, and are in a prime position to share information about clinical trials. A very important
provider in the institution and larger practice setting is the research nurse or study coordinator,
whose entire job is dedicated to clinical trial enrollment and monitoring of participants
throughout a study and for many months after treatment is completed. Often, however, a patient
does not speak with a research nurse until interest has been expressed either by the physician
or the patient in a clinical trial. It may thus be important to educate primary nurses so that they
can provide basic clinical research education that may lead to conversations about clinical trials
between patients and research nurses that might otherwise have been missed opportunities.
The Need for Enrollment in Ovarian Cancer Clinical Trials
Progress in preventing and curing cancer depends on informed participation in cancer
clinical trials (Comis, 2000). As the biomedical understanding of cancer expands, increasing
opportunities to test preventive, curative and palliative advances will require increasing numbers
of adults who are able to make informed decisions about participation in clinical trials (Comis et
al., 2003). Enrollment in cancer clinical trials has been consistently low in U.S. adults (Murthy et
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al., 2004), and accrual barriers have been studied, with results calling for interventions to
facilitate increased enrollment.
Informed decision-making about cancer clinical trials should occur as early as possible in
the treatment continuum; enrollment criteria usually limit eligibility by capping the allowable
number of prior therapies to up to three, except in phase I studies that are more focused on how
much of an agent can be administered safely rather than on therapeutic benefit (Daugherty et
al., 1995). Eligibility criteria require adequate performance status, thus waiting until multiple
therapies have failed and advanced disease has led to poor health may make eligibility for a
clinical trial unlikely, particularly for older patients, who may have more comorbidities and, while
at the greatest risk for cancer, are already underrepresented in clinical trials (Lewis, 2003).
Ovarian cancer, the most lethal gynecologic cancer with a mortality rate that has been
stable for more than three decades (ACS, 2013b), should be diagnosed and treated by a
gynecologic oncologist per National Comprehensive Cancer Network (NCCN) guidelines
(Stewart, Rim, & Richards, 2011). NCCN guidelines stipulate that women with persistent or
recurrent ovarian cancer should be offered a clinical trial (Morgan et al., 2011; Morgan et al.,
2013), because trials are a prerequisite to progress, which has extended survival in women with
advanced disease (Engelen et al., 2006), but failed to yield a curative discovery or preventive
screening test (ACS, 2013a).
The ovarian cancer SOC is changing quickly, with evolving strategies being tested in
clinical trials for their impact on overall and progression-free survival and quality of life.
Strategies include the use of neoadjuvant therapy in advanced ovarian cancer, the use of
biologic drugs that target specific gene pathways, the impact of various dose densities and
delivery routes (intraperitoneal and/or intravenous), and the role of antiangiogenic drugs and
maintenance therapies (Goff, 2013).

21

Barriers
The geographic influence of access to NCI-designated comprehensive cancer centers and
gynecologic-oncologist principle investigators who oversee clinical trials is a significant barrier
for women in rural and western regions of the United States (Riman et al., 1998), as discussed
in the paper that addressed question 2. However, even in major metropolitan areas where
leading subspecialty clinical research resources are accessible, women lack awareness and
have misperceptions about clinical trials that impede participation in much-needed ovarian
cancer clinical trials (Comis et al., 2003). Nonparticipation is compounded by the low incidence
and prevalence of ovarian cancer, challenging research-focused cancer centers to find
adequate numbers of participants for randomized clinical trials with sufficient statistical power.
The challenge of achieving adequate sample size has been aided by the collaborative efforts of
the Gynecologic Oncology Group (GOG). Comprised of more than 50 academic centers and
160 affiliate sites, the GOG was established in 1970 to sponsor controlled clinical trials to
answer questions about managing gynecologic cancers; to date, the GOG has conducted more
than 300 studies and published more than 550 manuscripts (GOG, 2013).
Numerous combined-gender studies of adults have identified barriers to participation
that include lack of awareness that clinical trials are an option and the presumption that the
standard of care is better than the investigational agent (Taylor & Leitman, 2001). Deterrents of
participation in clinical trials that have been found in multiple studies include concerns about
randomization and placebos, being treated like a “guinea pig,” encountering unpleasant side
effects, receiving a treatment that is inferior to the standard of care, and worry about cost, time,
travel, and the complexity of the informed consent process. Interestingly, Taylor and Leitman
(2001) found that among the 85% of cancer patients who said they were unaware that clinical
trials were an option, 75% said they would have attempted to enroll if they had known.
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Facilitators
Physician-based facilitators in women with gynecologic cancers were studied by Luck
and colleagues (2005), who found that women with a gynecologic oncologist for initial surgery
were more likely to enroll in clinical trials (P<0.001). Physicians who were primary investigators
were more likely to enroll patients in clinical trials (Mannel et al., 2003), while physicians with an
affiliative (friendly) communication style, as opposed to a dominant (controlling and contentious)
style, positively influenced patients who enrolled in clinical trials (Grant, Cissna, & Rosenfeld,
2000).
Surveyed clinical-trial participants (men and women with various types of cancer) said
they were motivated to advance medical science and help others, earn extra money, get better
treatment, improve health, respond to information seen or heard about the study, follow a
doctor’s recommendation, satisfy curiosity about a study, and, least often, seek a trial because
of the severity of their illness (Gullo, 2005a; Taylor & Leitman, 2003). An observational cohort
of patients, physicians, and nurses revealed the following patient-based correlates of
significance for clinical trial entry: perceived benefits and having the help of a clinical research
associate (CRA), doctor, or trial nurse in making the decision (P<0.05) (Wright et al., 2004).
In a breast-cancer patient population, physician recommendation was a significant factor
in a woman’s decision to enroll (Avis, Smith, Link, Hortobagyi, & Rivera, 2006). Studies of
facilitators in women with gynecologic cancers were associated with being 50 years of age or
younger, having education beyond high school, and having private insurance (Mathews,
Restivo, Raker, Weitzen, & Disilvestro, 2009). Facilitators in women with gynecologic cancers
that are similar to those found in mixed-gender populations include helping others, the need for
follow-up care, and protecting personal health (Shuhatovich et al., 2005).
Additional Challenges Associated with Ovarian Cancer Clinical Trials
Because the incidence of ovarian cancer is lower than that of many other cancers, it is
more challenging to get significant enrollment in ovarian cancer clinical trials. The GOG has
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assisted in meeting that challenge by forming collaborative networks comprised of cancer
treatment centers throughout the United States to support large multisite clinical trials (GOG,
ND). The concentration of gynecologic oncologists in US metropolitan areas, noted by Cooney
and colleagues (2011), translates into a shortage of those best able to lead ovarian cancer
clinical trials as principle investigators. Thus there are regional limitations that decrease access
to ovarian cancer clinical trials by women with advanced recurrent or persistent disease.
Ovarian Cancer Clinical Trial Resources in Florida
Florida, among the top half of states with a higher incidence of ovarian cancer (Figure
2.3), has about 85 gynecologic oncologists, dispersed mostly in counties with large cities, such
as Tampa, Orlando, Jacksonville, and Miami (Figure 2.4).

Figure 2.3. Invasive Cancer Incidence Rates by State in the United States
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Figure 2.4. Distribution of Gynecologic Oncologists in Approximated Upper, Middle, and Lower
Thirds of Florida
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Ovarian Cancer Clinical Trial Resources in Florida
Gynecologic Oncologists
Based on the preceding literature, physician recommendation has the greatest impact on
a patient’s decision-making about clinical trials. One of the greatest clinical trial resources for
women with ovarian cancer is, therefore, gynecologic oncologists who inform them about
opportunities for clinical trials either on-site or at another facility.
An informal web search of ovarian cancer clinical trials in Florida for women with
recurrent disease, via FloridaCancerTrials.org, done on December 30th, 2013, revealed 38
studies (three phase III studies in Tampa and Orlando; four phase II studies in Tampa, Orlando,
and Jacksonville; eight phase I/II studies mostly in Tampa and Orlando, also Sarasota; and
fourteen phase I studies, predominantly in Tampa, a couple in Orlando, five in Sarasota, five in
Jacksonville, and one in Miami. All were in or close to metropolitan areas.
Trial-Matching Resources
Web-based search engines enable those with access to computers to seek specific clinical trials
with descriptive overviews, a list of sites that offer them, and contact information for further
information. One of the most thorough, reputable and user-friendly sites is the National Cancer
Institute’s trial-search site that finds trials by location, type, treatment, drug, keywords, phase,
and sponsor at http://www.cancer.gov/clinicaltrials/search.
Especially useful for Floridians is the trial-matching tool
http://www.floridacancertrials.com/en/, powered by Emerging Med, supported by Grant Award
D1BIT10963-01-00 from the Office of Health Information Technology, Health Resources and
Services Administration, DHHS, and designed to allow persons to enter details about their type
of cancer and be matched according to a high level of detail to potentially suitable clinical trials
statewide.
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A Theoretical Approach to Framing Clinical Trial Enrollment
Consolidated Framework for Implementation Research (CFIR)
The theoretical basis for my gynecologic-oncology systems-based research is the
Consolidated Framework for Implementation research (CFIR). CFIR includes the elements of
intervention characteristics, the outer setting, the inner setting, characteristics of individuals, and
the process (Damschroder et al., 2009), as shown in Figure 2.5. Among the intervention
characteristics are its source, evidence strength and quality, relative advantage, adaptability,
trial-ability, complexity, design quality and packaging, and cost. Note that the intervention in this
application is enrollment in a clinical trial. It is important to understand that the intervention box
on the left depicts enrollment as it currently exists, which is why it is shown as a detached
rectangle; the detachment is synonymous to the presumption that

Figure 2.5. CFIR Domains: Outer Setting, Inner Setting, Intervention, Process (adapted from
Damschroder L, Aron D, Keith R, Alexander J, Lowery J – Fostering implementation of Health
Services Research Findings into Practice)
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the intervention, enrollment in ovarian cancer clinical trials, with better understanding necessary
and sufficient factors as well as facilitators and barriers, may be improved through informed
interventions that target the outer and inner settings and enrollment process. Thus the
“attached” rectangle on the right indicates the adapted enrollment process after informed efforts
have targeted the outer and inner settings, including individuals, and the overall process.
Applying CFIR to Ovarian Cancer Clinical Trials
The outer setting for CFIR is shown in Table 2.5; for this study the outer setting will be
comprised of gynecologic-oncology departments within institutions and community-based
practice settings in Florida. The inner setting (see Tables 2.6 to 2.9) encompasses structural
characteristics, e.g. of an institution or departments, networks and communication, culture,
characteristics of the climate for implementation, and readiness by leaders, access to resources
and information and knowledge.

Table 2.5. Outer Setting
Public Resources
• Does your practice have a website? (Q22)
• Does your practice have clinical trial resources for patients?
(Q47)
• Does your practice provide patient education literature on
clinical trials? (Q31)
Professional Resource
• Does your practice educate staff about clinical trials? (Q34)
• Does your practice have resources to help you answer
questions about clinical trials? (Q43)
Cosmopolitanism
• The size of the community you serve
External Incentives
• Does your practice ever appear in local publications such as a
newspaper? (Q24)
• Has your practice been featured or promoted on local TV or
radio? (Q25)
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Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
rural / small town OR
city / major urban area
Yes or No
Yes or No

Table 2.6. Inner Setting: Structural Characteristics for Practice Nurses
Total Medical Oncologists (Q6) Gynecologic Oncologists (Q7) / nurse
practitioners (Q8) / primary nurses (Q9)/ research nurses on staff (Q10).
With what hospital(s) is your practice linked for surgeries and treatment? (Q21)
Do you have an on-site infusion center? (Q20)
Race of ovarian cancer patients with stage III/IV disease treated on site in the
last 12 months (Q18 - 19)
% white
% black
% Asian
Ethnicity of ovarian cancer patients with stage III/IV disease treated on site in the
last 12 months
% Hispanic
% nonHispanic
About how many women with ovarian cancer were seen in your practice in
2013? (Q13)
About how many women with ovarian cancer were enrolled in clinical trials at
your site in 2013? (Q14)
About how many women with ovarian cancer were referred to another practice
for a clinical trial in 2013? (Q15)
Does your practice have on-site clinical trials for ovarian cancer patients? (Q11)
Does your practice ever refer ovarian cancer patients to other sites for the
purpose of participating in a clinical trial? (Q12)

Numeric
values
Text write-in
Yes or No

Values

Values
Values
Values
Yes or No
Yes or No

Table 2.7. Inner Setting: Networks/Communication Culture for Practice Nurses
When ovarian cancer clinical trials are discussed with patients, who is most likely
to bring up the topic? (Q28)
• The patient
• The physician
• Nurse practitioner Primary care nurse
• Research nurse
Does your practice have a plan for presenting the option of a clinical trial to
women with ovarian cancer? (Q27)
Does your practice provide ovarian cancer patient education on any of the
following? (Q23)
• Treatment
• Symptoms
• Clinical trials
• Support groups
Which of the following should be able to talk about ovarian cancer clinical trials
with patients? (Q29)
• Physicians
• Nurse practitioners
• Primary care nurses
• Research nurses
Table 2.7 continues on next page.
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Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

Yes or No
Yes or No
Yes or No
Yes or No

Yes or No
Yes or No
Yes or No
Yes or No

Table 2.7 (continued)
Do you ever use clinical trial websites? (Q32)
Does your team have a plan for offering clinical trials to women with recurrent or
persistent ovarian cancer? (Q45)
Does your team discuss ovarian cancer clinical trials during team meetings?
(Q46)
If a patient asks about clinical trials, is she referred to the doctor for further
discussion? (Q48)
If you don’t have a clinical trial for a woman with ovarian cancer who wants one,
do you have a plan to help her find one? (Q49)

Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

Characteristics of individuals within the inner setting of medical or gynecologic oncology
departments within institutions and community-based practice settings would include knowledge
and beliefs about the practice or intervention, in this case offering a clinical trial, self-efficacy,
individual stage of change, one’s identification with an organization, and additional personal
attributes. Key persons within medical and gynecologic oncology departments within institutions
and community-based practice settings would include medical and gynecologic oncologists,
PAs and ARNPs, research nurses, and nurses who provide outpatient and inpatient care for
women with ovarian cancer.

Table 2.8. Inner Setting: Implementation, Incentives, Learning Climate for Practice Nurses
Do you think ovarian cancer clinical trials are a priority at your facility? (Q30)
Do you have computers in the waiting area for patients’ use? (Q33)
Do you ever use clinical trial websites? (Q32)
Does your practice provide patient education literature on clinical trials? (Q31)
Does your practice educate staff about clinical trials? (Q34)
Does your practice have resources to help you answer questions about clinical
trials? (Q43)
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Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

Table 2.9. Inner Setting: Practice Nurses
Knowledge
Do you believe that health insurance covers standard-of-care costs in a clinical
trial? (Q35)
Do you think the ACA will be helpful in covering CT costs? (Q36)
Do you want to know more about clinical trials? (Q44)
Beliefs
Should ovarian cancer patients be informed about clinical trials as early as
possible after being diagnosed? (Q37)
Should clinical trials be the last resort after all known treatments fail? (Q38)
Self-Efficacy
Are you comfortable answering patients’ questions about clinical trials? (Q41)
Do you feel well informed when patients ask about clinical trials? (Q42)

Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

Process elements include planning, engaging one’s opinion leaders and champions, executing,
and reflecting and evaluating (Damschroder et al., 2009). For indicators associated with process
elements, see Table 2.10.
Table 2.10. Process: Planning, Engaging, Executing for Practice Nurses
Does your team have a plan for offering clinical trials to women with recurrent or
persistent ovarian cancer? (Q45)
Does your practice educate staff about clinical trials? (Q34)
Does your practice provide patient education literature on clinical trials? (Q31)
Does your practice have resources to help you answer questions about clinical
trials? (Q43)
If a patient asks about clinical trials, is she referred to the doctor for further
discussion? (Q48)
If you don’t have a clinical trial for a woman with ovarian cancer who seeks a trial,
do you have a plan to find her one? (Q49)

Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

In addition to demographics that will be provided in a subsequent chapter, women with ovarian
cancer were asked one behavior question (have you ever been in a clinical trial?) and an
intention question (are you likely to agree to participate if offered a clinical trial?). Questions
related to the theoretical inner setting were also asked of the participants who were women with
ovarian cancer (Tables 2.11 through 2.14).
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Table 2.11. Inner Setting: Structural Characteristics for Women with Ovarian Cancer
Has your doctor or nurse ever discussed clinical trials with you? (Q8)
Does your oncologist offer clinical trials? (Q14)

Yes or No
Yes or No

Table 2.12. Inner Setting: Networks/Communication Culture for Women with Ovarian Cancer
Which of the following providers of care have ever suggested you think about a
clinical trial? Check all that apply (Q13)
• Oncologist
• Nurse practitioner
• Research nurse
• Primary care nurse
• Family member
• Friend
• No one
If you wanted a clinical trial that your practice didn’t offer, do you think your
doctor would help you find a facility that offers the trial? (Q22)
Do you think website information for any of the following topics is helpful? Check
all that apply (Q28)
• Treatment
• Symptoms
• Clinical trials
• Support groups

Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

Yes or No
Yes or No
Yes or No
Yes or No

Table 2.13. Inner Setting: Implementation, Incentives, Learning Climate for Women with
Ovarian Cancer
Have you ever seen patient education literature on clinical trials in your doctor’s
office? (Q17)
Does your oncologist have a website? (Q26)
If your oncologist had a website that helped you find matching clinical trials,
would you use it? (Q27)
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Yes or No
Yes or No
Yes or No
(why)

Table 2.14. Inner Setting: Women with Ovarian Cancer
Knowledge
Do you believe that health insurance covers standard-of-care costs in a clinical
trial? (Q29)
Do you think the ACA will be helpful in covering CT costs? (Q30)
If your doctor or nurse mentions clinical trials, do you want to know more? (Q15)
Beliefs
Do you think it makes sense to consider a clinical trial right after you are diagnosed
with cancer? (Q18)
Do you think clinical trials are an option to be considered only if other treatments
stop working? (Q19)
Self-Efficacy
Are you comfortable answering bringing up the subject of clinical trials to your
doctor? (Q16)
If a clinical trial required extra visits, would that stop you from participating? (Q23)
If a clinical trial meant traveling an extra 30 miles each visit, would that stop you
from participating? (Q24)
Would your family be supportive if you were in a clinical trial? (Q25)
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Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No
Yes or No

CHAPTER THREE: METHODOLOGY
Purpose of the Study
The primary purpose of this multiple case study was to identify the necessary and/or
sufficient factors that are instrumental in making clinical trials accessible to women with
persistent or recurrent ovarian cancer in the state of Florida. The secondary purpose was to
identify facilitators and barriers within the gynecologic oncology practice setting that, in the
longer term, may be used to inform targeted interventions to improve trial access and accrual.
Research Questions
This multiple case study attempted to answer the following research questions:
1. What necessary and/or sufficient factors, based on Qualitative Comparative
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in
a clinical trial?
2. What barriers and facilitators exist with regard to enrolling women with ovarian
cancer in clinical trials?
To answer the preceding research questions, I proposed a multiple case study using
mixed methods to determine necessary and/or sufficient factors, as well as barriers and
facilitators, to enrollment by women with recurrent or persistent ovarian cancer in clinical trials in
Florida. The theoretical framework for the study is the Consolidated Framework for
Implementation Research (CFIR), which was explained in chapter two.
Rationale for the Approach
Mixed methods have multiple purposes in research that can include triangulation,
complementarity, initiation, development, and expansion (Greene, Caracelli, & Graham, 1989).
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In addition to multiple purposes for using mixed methods, there are multiple strategies for
combining them, and the logical approach in this multiple case study was to use a survey that
would provide quantitative and qualitative data. Quantitative findings would be interpreted via
Qualitative Comparative Analysis (QCA, explained in a subsequent section of the chapter), and
the answers to open-ended questions would provide qualitative data to explain quantitative
findings and triangulate, or show whether there is convergence between/among cases with
similar findings on various constructs in the CFIR theoretical framework (Ulin, Waszak, &
Pfannenschmidt, 1996). QCA, notably, is useful for case studies for which little preexisting
research has been done, and when there is a relatively small number of cases for which the
researcher seeks clarification of causal patterns (Donnelly & Wiechula, 2013). QCA enables
cross-case comparisons that show what conditions are “sufficient” for an outcome of interest
(Ragin, 1989). In this case, the outcome of interest was enrollment in a clinical trial. QCA was
thus used to determine variables associated with high and low (or no) enrollment in clinical trials
by women with ovarian cancer and by nurses affiliated with gynecologic or medical oncology
practices that see women with recurrent or persistent ovarian cancer in Florida.
The outcome of interest is enrollment in clinical trials by women with ovarian cancer. The
influents of enrollment were sought for two populations: women with ovarian cancer and nurses
in medical or gynecologic oncology practices. Both specialties were included because there are
many more medical than gynecologic oncologists, and many women with ovarian cancer opt to
have chemotherapy closer to home, administered by a medical oncologist. Further, some
medical oncologists offer clinical trials or refer their patients to gynecologic oncologists for
clinical trials. The influents were considered within the five domains of the Consolidated
Framework for Implementation Research (CFIR) in Table 3.1 on the following page.
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Table 3.1. Five Domains of the Consolidated Framework for Implementation Research (CFIR)
Domain
Intervention
Inner Setting
Outer Setting

Individuals Involved
Implementation
Process

Description and Examples of Associated Constructs
Characteristics of the intervention such as complexity, cost, and
relative advantage.
Structural, political, and cultural contexts through which
implementation proceeds: organizational structure, social architecture,
communication/networks, and implementation climate and readiness.
Economic, political, and social context in which an organization
resides. Includes the extent to which the organization has an accurate
knowledge of patient needs, billing and reimbursement, funding
constraints, and ties to external organizations.
Individuals in the inner or outer setting can promote the
implementation process and alter program effectiveness via their
actions, which are influenced by attitudes and motivations.
Actions that lead to implementation, protocol and procedures.

The steps for performing QCA are listed in Table 3.2.

Table 3.2. Steps Used to Perform the Crisp Set Qualitative Comparative Analysis*
1. Define and operationalize the outcome
of interest, and assign dichotomous
scores for the outcome.

2. Select Cases
3. Identify key conditions, use
dichotomous score for each condition and
create a data matrix of scores for
conditions.

Outcome is enrollment in a clinical trial, defined as
consenting to participate in a study. Whether a
woman completed the clinical trial was not a
condition of interest in this study. The outcome of
interest was operationalized by survey questions
discussed in earlier sections.
Enrollment was 1 for yes and 0 for no.
All 20 patients who responded were included. One
of 7 nurses who responded did not answer all the
questions and thus had to be excluded.
Many questions were asked of nurses and patients
for the purpose of gaining quantitative and
qualitative information on the cases that would help
inform conditions within the five domains of CFIR. It
was anticipated that most of the information from a
case study would pertain to intervention, inner
setting, and the individuals involved. Most
questions were dichotomous “yes or no,”
supplemented by several open-ended questions to
gather qualitative data. Dichotomous questions
were coded as 1 for yes (present) and 0 for no
(absent). A data matrix (Table 4.38) was created
for the outcome and key conditions.

Table 3.2 continues on next page.
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Table 3.2 (continued)
4. Determine the analyses.

Conditions for enrollment in clinical trials were
analyzed for sufficiency solely or in combination
with other factors. A necessary factor would be the
existence of a clinical trial, but that in and of itself
would not necessarily be sufficient to enroll a
participant
5. Create a truth table.
fsQCA 2,0 was used to create a truth table to show
possible configurations of selected conditions
(Table 4.39).
6. Analyze the truth table and resolve
Table 4.39 shows those enrolled versus those
contradictions.
never enrolled in a clinical trial, juxtaposed with the
conditions of interest.
7. Use software to a find solutions by
Use fsQCA 2.0 to perform a standard analysis to
making multiple comparisons of case
identify conditions associated with enrollment
configurations in the truth table.
versus nonenrollment. fsQCA uses the QuineMcCluskey algorithm (based on Boolean
simplification) to make multiple comparisons of
case configurations in the truth table. High
consistency scores are used to choose prime
implicants. The software then generates a
complex, intermediate, and parsimonious solution.
8. Find out of the influence of conditions
Compare conditions to see if presence and
has symmetry.
absence conform to those with and without the
desired outcome (enrollment in a clinical trial).
9. Assess consistency and coverage of
Overall solution consistencies should be 1 (present
the solutions.
for all cases with the desired outcome).
10. Interpret solutions and create causal
Association with an outcome does not assume that
models.
conditions caused the outcome. Solutions can be
applied to frameworks to help develop models of
causality.
*Note that this table is guided by steps published in 2013 (Cragun et al., 2013).
Potential Significance
While there is speculation as to the factors associated with clinical trial enrollment
patterns by women with recurrent or persistent ovarian cancer, to date there are no studies that
systematically measure necessary and/or sufficient factors associated with trial enrollment in
Florida, looking at both patients’ and providers’ perceptions. This study was intended to identify
necessary and/or sufficient factors associated with trial enrollment as well as barriers and
facilitators within Florida’s gynecologic oncology institutional and community practice settings.
Findings could be used to inform subsequent research and interventions for more equitable
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statewide access to resources in accordance with the NCCN guideline on clinical trial options
for women with recurrent or persistent ovarian cancer in Florida.
The Study Populations
The study population was comprised of women who were diagnosed with ovarian cancer
and nurses in medical or gynecologic oncology practices, not all of which offer clinical trials on
site. Some practitioners, however, may be part of a collaborative or referral network for the
purpose of helping women with ovarian cancer enroll in clinical trials. The inclusion of both
specialties was necessary because many women with ovarian cancer opt to have adjuvant
chemotherapy close to home, administered by a medical oncologist. The low number of
gynecologic oncologists compared to medical oncologists compared to gynecologic oncologists
would have made it difficult or impossible to find 20 unique practices. The goal was to determine
clinical trial enrollments and/or referrals in the 20 unique practices—it would have been
impossible to find that many gynecologic oncology practices.
Study Schema and Proposed Timeline
The survey included demographic data, tied to the constructs, as well as potentially necessary
and/or sufficient factors related to enrollment in clinical trials. The proposed timeline for this study
was one year, with possible delays anticipated with regard to regulatory processes associated with
the scientific review committee at Moffitt Cancer Center and the University of South Florida
institutional review board, as well as unanticipated recruitment challenges. Regarding recruitment, it
was hoped that an incentive would enable timely recruitment and completion of the survey by 20
women with ovarian cancer and by 20 nurses in medical or gynecologic oncology practices.
The following study materials were created for IRB review and approval:
1. Study protocol for submission to the IRB along with the following:
2. A print version of the on-line nursing and patient surveys created in Qualtrics Invitation
letter (1) and email (2) reminders to increase responses using the Dillman method
adapted for online surveys, which is the use of mixed modes (mail and email for
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example), shorter time between contacts, and a diminished overall length the reminder
period (Dillman, 2000; Parsons, 2007). The letters described the purpose of the study
and invited them to take an online survey, for which they would receive a $20 incentive
for completion of the survey. See the appendices for the letter and follow-up emails sent
to nurses and to patients.

Figure 3.1. Study Schema
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Recruitment
Recruitment of Women with Ovarian Cancer
Moffitt Cancer Center launched the Total Cancer Care (TCC) protocol in 2006, in which every
patient at Moffitt is invited to provide written informed consent to allow their biospecimens and
clinical data to be used for ongoing research, and to agree to be contacted for opportunities for
voluntary participation in emerging studies that may relate to their specific cancer
diagnosis/predisposition and thus potentially be beneficial to them or others. Using the TCC
protocol, the following data (Table 3.3) was requested on July 17, 2014 for all women over age
18, diagnosed with stage III/IV ovarian cancer, who presented to Moffitt Cancer Center between
January 1, 2010, and June 30, 2014, who were still living on the data-request submission date.
On October 1, 2014, TCC provided the requested data for 118 cases. It was hoped that a chart
review would reveal at least 20 unique referring practices, which would comprise the target
mailing to practice nurses. Notably, the data provided by TCC did not include names of four
women with ovarian cancer known to the investigator from participation in a different study, and
those patients were added to the list. Patients for whom a referring practitioner’s name was
available were selected to receive the initial invitation letter. The chart review for 20 unique
practices yielded 60 cases with a unique referring provider, which was the starting point for
patient and nurse recruitment.
Table 3.3. Variables Requested from TCC on 7/17/14
Medical Record Number
TCC ID number
Histology code
Histology behavior
First & last name
Primary site
Class of case
TNM stage
Date of last contact
Race
Ethnicity

Date of Diagnosis
Survival time in months
Treatment summary
Age at diagnosis
Current age
Marital status
Date of first contact
Telephone number
Postal code
County
Street address
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TCC query results for patients. The intention was to include patients for whom the
referring physician’s name and address were available, to see if responses of both patients and
practice nurses would be congruent, but with a very low yield of responses from the 20
practices, that strategy was not possible. Moreover, the TCC list omitted several women who fit
the inclusion criteria whom the PI knew from prior study involvement. A mailing and follow-up
calls to 31 women who were on the TCC list led to 12 consented women who completed the
online survey (Table 3.4). Needing 7 more participants, the PI contacted 4 women who were not
listed in the TCC data output but who fit the inclusion criteria; all 4 women were consented and
completed surveys. Three more women were needed, thus the PI contacted a liaison with the
nonprofit ovarian cancer support group Ovacome, which yielded 4 more women who provided
written informed consent and completed surveys. The recruitment sources for the sample of
women with ovarian cancer are shown in Table 3.4.
Table 3.4. The recruitment sources of women with ovarian cancer who were consented and
provided completed surveys (N=20).
Source of consented participants
TCC data output
Eligible Moffitt patients not in TCC output
Ovacome referrals

N
12
4
4
Total 20

%
60%
20%
20%
100%

Letters with enclosed consent forms and prepaid addressed return envelopes were
prepared and posted on August 19, 2014, to the 60 patients for whom referring provider
information was available. By September 23, 2014, 12 women had returned signed informed
consent forms, and by January 15, 2015, all 12 had completed the survey. Follow-up calls were
made to those who did not respond, and messages were left only if there was an opportunity;
follow-up calls did not influence any who did not initially provide informed consent. At that point,
with follow-up calls failing to increase the number of consented participants, the four women that
were not on the TCC data output file were contacted, via letter and consent form mailed
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February 2, 2015, and all had consented by February 14 and completed the survey by February
18, 2015. With the additional four participants, the sample total was 16, and four more women
were contacted by using the investigator’s connection with Ovacome, an all-volunteer,
501(c)(3) nonprofit organization founded in 1999 to provide support and education to women in
the Tampa Bay area who are diagnosed with ovarian and other gynecologic cancers. The
Director of Ovacome provided the names of six women, to whom letters with enclosed consent
forms and return envelopes were mailed on March 10, 2015. By March 23, four had returned
signed consent forms, and by March 28, 2015, all four had completed the survey, yielding a total
of 20 enrolled women who had completed surveys. The time it took from the initial mailing on
August 19, 2014, to having twenty completed surveys on March 28, 2015, was thus 222 days,
or 31 weeks and 5 days.
Recruitment of Nurses
The goal for nurse recruitment was to have 20 nurses, each from a different practice,
complete the survey, and to have a spread of nurses that included one from Moffitt and one
from TGH, with the balance from solo gynecologic or medical oncology practices throughout the
Tampa Bay area. The differing sites and practice types were desired to provide a realistic array
of variables across practices that treat women with ovarian cancer. The purpose was not to
recruit multiple nurses from one site, particularly from Moffitt Cancer Center, where clinical
research is integral to the culture. To do so would have introduced bias.
TCC query results for practice nurses. On July 17, 2014, a request for data from the
Total Cancer Care (TCC) protocol was made for all women over age 18, diagnosed with stage
III/IV ovarian cancer, who presented to Moffitt Cancer Center between January 1, 2010, and
June 30, 2014, who were alive as of the data-request submission date. The query yielded a
data file that was provided October 1, 2014, for 118 cases. The next task was to identify those
for whom the name of a referring provider was included, and 60 cases (51%) included unique
names of referring physicians. A Google search was used to identify practice addresses for
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mailings to the provider’s primary nurse, which reduced the number of cases to 20. Ultimately,
after contacting the 20 practices using the Dillman method (letter followed by telephone calls),
only two surveys were completed by nurses.
The starting point for locating referring providers was the list of 60 ovarian cancer
patients for whom chart reviews yielded specific referral information. Each referring provider
name was “Googled” for a practice address, and twenty referring doctors’ names and addresses
were located. Letters and envelopes were addressed to the attention of “The Primary Nurse for
Dr. ‘Doe’” and mailed on October 20, 2014; consent was part of the on-line survey, and the
letter requested a telephone call so that the investigator could obtain the nurse’s email address
and provide the link to the survey. In other words, the letters to nurses were depersonalized
because the investigator did not have a name or an email address. Getting those identifiers
would have to occur as a result of the nurse receiving the depersonalized letter and calling the
investigator to provide contact information consisting of email address and telephone number
and extension. There were no responses within two weeks, thus follow-up calls began the first
week of November; calls were answered by an operator or receptionist who would ask if the
caller was a patient. In one instance, upon explaining the purpose of the call, the receptionist
said that any kind of survey would have to be approved by the business manager and that the
process could take months. Only one follow-up call reached a nurse, who expressed that she
was extremely busy and wrote down the survey link and said she would try to get to it when she
had time. A call-back two weeks later produced the same statement; ultimately, the survey was
never completed by that particular nurse. The nurses from Moffitt and Tampa General Hospital
were known to the investigator, and both nurses completed the survey within two weeks of
being asked. An email requesting nursing leads at other oncology practice sites was sent to six
gynecologic oncology nurses and two gynecologic oncology nurse practitioners and one
gynecologic oncology physician assistant on December 8, 2014. The primary nurses stated that
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they did not know nurses at other practice sites in the Tampa Bay area, and one nurse
practitioner suggested a closer connection to the University of South Florida (USF) College of
Nursing. The low response rate for nurses led to consultation with two nursing professors. One
professor sent email requests to several nurses, which precipitated five additional surveys, one
of which could not be used because only two-thirds of it was completed, bringing the total to six
completed surveys by December 17, 2014. The next strategy, which was approved by Moffitt’s
Science Review Committee and the USF IRB on May 5, 2015, was to include an announcement
in the USF College of Nursing newsletter, inviting nurses to follow the link to the survey and
receive a twenty dollar incentive upon completion. This strategy yielded just one additional
survey, for a total of seven surveys completed by practices nurses as of June 18, 2015. The low
response rate by practice nurses will be discussed in the results section.
Method of Survey Analysis
The analytic method for the quantitative items in the survey was Qualitative Comparative
Analysis (QCA), which was selected because it offers a practical approach to understanding
complex real-world situations. QCA was created for case study research to derive solutions that
include a list of factors that, if absent or present, are uniquely associated with an outcome
(Ragin, 1989). QCA allows the researcher to build models by determining which conditions, in
combination, are necessary and/or sufficient for a particular outcome. QCA is particularly useful
in situations involving case studies with little preexisting research, and in which there is a
relatively small number of cases suited to dichotomous variables, and when the researcher
seeks to understand or interpret causal patterns; QCA findings are presented using Venn
diagrams and truth tables, must be directly related to the cases being studied (e.g., the
institutions and practice settings), and should explain the Boolean notation in conjunction with
the resulting narrative (Donnelly & Wiechula, 2013; Schneider & Wagemann, 2010).
Although qualitative and quantitative research tend to be used comparatively (Bazeley,
2009) and are not usually combined within one procedure (Ragin, 1989), QCA has not only
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been used successfully in case study research in the realm of political science, but has recently
been used to determine factors related to variable outcomes across fifteen institutions that
provide universal tumor screening programs to identify patients with Lynch syndrome, which is
the predominant cause of hereditary colorectal cancer (Cragun et al., 2014; Cragun et al.,
2013). Cragun and colleagues (Cragun et al., 2014), in examining the use of QCA, noted the
method’s significance in assessing the value of solutions and in building models by deriving
components of necessity and/or sufficiency for a desired result. Donnelly and colleagues (2013)
used QCA to study the role of clinical placement, nursing education and patient outcomes in a
case study (n=16) that involved a questionnaire and interviews.
Using Crisp versus Fuzzy Set Data
QCA, applying set theory to seek a combination of causal conditions, has two variations:
crisp set, which is being present or not (csQCA), and fuzzy set, which has a range of “gray”
options that exceed the dichotomous on or off options of crisp-set QCA (fsQCA) (Rihoux, 2006).
Strong speculation is that many of the community-based practices do not have clinical trial
resources, but this has not been systematically documented. With documentation, along with a
dimension that probes for reasons and identifies barriers and facilitators, proposals for
interventions can be created with requests for funding and support to increase clinical trial
enrollment access for women with recurrent or persistent ovarian cancer throughout Florida. If
speculation is accurate, which, especially considering the distribution of gynecologic oncology
practitioners in conjunction with the fact that ovarian cancer is one of the more rare, albeit
deadly cancers, it is likely that many community-based practices do not have the resources to
offer clinical trials to patients with persistent or recurrent disease. With that consideration in
mind, most of the questions that were asked, except for demographics, are conditions that are
either present or not, making the crisp-set variant preferable for this study.
In questions for which numbers are desired, answers can be dichotomized by using two
categories of numeric ranges, for example having 0-3 or 4-6 gynecologic oncologists at a
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treatment center. By using QCA to develop survey questions, one may identify factors that are
necessary and/or sufficient for women with recurrent/persistent ovarian cancer to be enrolled in
clinical trials at various facilities throughout the state of Florida. A cause is considered
necessary if it is required for an outcome; a cause is considered sufficient if it can produce an
outcome by itself (Ragin, 2008).
Survey of Nurses in Gynecologic or Medical Oncology Practices
Nurse respondents were put into two groups:
•

Practices that enrolled at least one ovarian cancer patient in an on-site clinical trial or referred
her to another site for a clinical trial in the last 12 months.

•

Practices that neither enrolled nor referred an ovarian cancer patient to another site for a
clinical trial within the last 12 months.

Source of Data
Data comes from the on-line survey completed by a primary care or research nurse who
enrolls in or refers women with ovarian cancer to clinical trials. Most of the data, except for
several write-in demographic questions, is quantitative, blending nominal demographic data with
dichotomous data structured for Qualitative Comparative Analysis (QCA), as described in the
preceding section and is being now explained in terms of its application to the preceding
dependent variable: high or low enrollment in ovarian-cancer clinical trials. QCA survey
questions have dichotomous choices—presence or absence, 1 or 0, except for a few exceptions
in which numeric ranges are broken into two spans. The fsQCA2.0 software, upon data entry,
will analyze which independent variables in the survey, alone and in combination, are present
for each of the three conditions of the dependent variable, enrollment (high, low, mid-range).
The software generates a truth table, each row of which is an independent variable.
Survey Design
On-line survey development using Qualtrics. Survey design requires care in writing
succinct, clearly worded questions that avoid jargon or abbreviations, ambiguity, emotionality,
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double-barreled and leading questions, and complexity that disincentivizes the respondent
(Neuman, 2006). Because some of the survey questions are related to practice demographics, it
was important to clarify that the survey could be saved and returned to later in case answering a
question required discussion with another team member.
Questions for demographics preceded questions associated with the theoretical
constructs of the CFIR domains, and were asked of two populations: nurses in medical or
gynecologic oncology practices, and women diagnosed with ovarian cancer. Refer to the
appendices for the surveys, which were provided via email with a link to an on-line survey
executed in the Qualtrics platform.
Reliability and validity. Content validity was reviewed by asking research nurses if key
factors were missing, if irrelevant factors existed and should thus be deleted, and if wording was
accurate and succinct. No other measure of this type exists, and the variables were linked to
theoretical constructs. With regard to reliability, a test-retest pilot was conducted on several
research nurses before launching the final survey. The same procedure was done with the
survey for patients, using a subset of women with ovarian cancer to make sure the survey
wording was accurate and straightforward.
Issues Related to Self-Reported Survey Research
Self-reported survey data always has limitations related to recall, cognitive skills,
individual commitment, environmental distractors, and bias (Streiner & Norman, 2008).
Inference and estimation. The risk with inference and estimation is over- or
underestimating and missing a rare exception that may have occurred, especially with the use
of crisp-set QCA, that imposes dichotomous response choices that will challenge the research
nurse to recall actual events and categorize them into absolute values such as all or none
categories or broad ranges. Depending on the question, this could be easy or difficult, but for
patterns related to ovarian cancer clinical trial practice procedures, since ovarian cancer is a
rare cancer, this should not be overly challenging. Moreover, ovarian cancer clinical trials,
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although available at some of the larger centers, per an on-line search that was done recently,
did not appear to be prevalent throughout the state of Florida.
Social desirability. There was the risk that the nurse who completed the survey would
be under pressure to make the practice “look good” in terms of enrollments and offers of clinical
trials to patients. To achieve a positive image, she or he may thus be tempted to exaggerate
responses in the positive direction to give the impression that more trial offers are made to
women with persistent or recurrent ovarian cancer than are the case. In an effort to reduce this
risk, an introductory plea for accuracy was made so that findings could accurately inform future
interventions that might provide useful tools and build collaborative networks. In every
dimension of the study, the importance of honesty, accuracy, and integrity was emphasized.
Sampling and recruitment. Sampling started with a query to the Total Cancer Care
protocol to release a data output file; referring practices were selected from that file for
generating letters to practice nurses. The TCC data file was to include all women over age 18,
diagnosed with stage III/IV ovarian cancer, who presented to Moffitt Cancer Center between
January 1, 2010, and June 30, 2014, who were still living on the data-request submission date.
Upon receiving the data file, the investigator would conduct chart reviews to find cases for
whom the name of a referring provider was available. It was hoped that the incentive of a $20
gift card would achieve a 60% rate of response, or survey completion by 36 nurses.
Survey Data Analysis
This is a multiple case study with a small sample size, which is why QCA is an
appropriate analytic method. The quantitative survey data would be analyzed using the
fs/QCA2.0 software, downloaded at no cost from a link made available by Dr. Charles Ragin,
who explained that this software package can be used for both crisp and fuzzy set analysis
(Personal communication via email with Charles Ragin on Sunday, January 5, 2013). The QCA
method was discussed in the preceding section.
The following steps were undertaken; 2 through 7 are adapted from Cragun (2013):
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1. Create a codebook of all independent variables, separating demographic data from
dichotomous QCA data.
2. Create a QCA data matrix with membership scores for the outcome (enrollments) and
key conditions per case (practice).
3. Determine whether a necessity analysis is needed. If not, conduct only a sufficiency
analysis.
4. Using fsQCA2.0, create a truth table showing all possible configurations of selected
conditions.
5. To resolve any contradictions that may exist, add an additional condition to create a
revised truth table.
6. Use fsQCA2.0 to conduct a “Standard Analysis” to detect conditions associated with
HPEs (high patient enrollments), generating three solutions: complex, parsimonious,
and intermediate.
7. Determine if conditions associated with HPEs are the same as those with low (~HPE)
by repeating steps 3 to 6 and using ~HPE as the outcome.
The qualitative data from the open-ended survey questions would be analyzed by
identifying themes for the purpose of explaining and better understanding the quantitative
findings and will be found along with descriptive statistics and QCA findings in the results
section.
Anticipated Problems and Plans for Troubleshooting
This multiple case study included hospital- and community-based gynecologic oncology
practices. Community-based practices linked to small hospitals are presumed to have less
resources than practices linked to large metropolitan hospitals. Those differences were to be
explored with the inclusion of several survey questions about practice resources, e.g. staff
receives training, a practice website and/or clinical trial search tool exists, patient education
materials on clinical trials are available in the practice.
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A challenge at the beginning of the study was anticipated with regard to gaining the
attention of the nurses asked to complete the online survey. It was hoped that the incentive
would be sufficient, and presumed that the greatest hurdle would be reaching the primary
practice nurse with the invitation to participate. It was also hoped that an introductory letter
followed by a telephone call would yield a nurse’s name, telephone number, and email address.
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CHAPTER FOUR: RESULTS
Descriptive Statistics for Participating Practice Nurses and Women with Ovarian Cancer
Practice Nurses
Eleven nurses began the survey but four stopped after they answered question number eight,
which asked for the number of nurse practitioners in the clinic; question nine asked how many
primary care nurses were in their clinic. Seven practice nurses completed the entire survey;
one, a research nurse, was from Moffitt Cancer Center, one was from Tampa General Hospital,
and five were with Florida Cancer Specialists at five different practice sites, in Tampa, Hudson,
Largo, Venice, and Clearwater. More than half of the practices reported having at least one
research nurse in the clinic, and offering on-site ovarian cancer clinical trials (see Table 4.1).
Table 4.1. Practice nurses who reported having a research nurse in their clinic and having onsite clinical trials for ovarian cancer patients?
Yes
4
No
3
Total
7
Variance: 0.29; Standard Deviation: 0.53

57%
43%
100%

Interestingly, although four practices reported having on-site clinical trials for ovarian cancer
patients, only one nurse reported enrolling a woman with ovarian cancer in a clinical trial since
2013, and one of the practices (Tampa General) had referred three women with ovarian cancer
to another facility for a clinical trial (see Table 4.2).
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Table 4.2. Women with ovarian cancer enrolled in clinical trials at your site, or referred to
another site, since 2013.
About how many women with ovarian cancer
were enrolled in clinical\trials at your site in
2013?
0
26
0
0
0
Unanswered
0

About how many women with ovarian cancer
were referred to another\practice for a clinical
trial in 2013?
3
Unknown
Don’t know
0
0
Unanswered
Unknown

Nurses estimated the racial breakdown of their practices, averaged for all seven responses, to
be 76% white, 15% black, 5% Asian, and 3% unknown (see Table 4.3A). The proportion of NonHispanic to Hispanic ethnicity was, on average, 93% and 7% respectively (Table 4.3B).
Table 4.3. Practice nurses’ estimated distribution of patients’ race and ethnicity.
A. Estimated racial stratification of ovarian cancer patients.
Average
Standard
Answer
Min Value Max Value
Value
Deviation
White or
13.00
100.00
76.14
31.37
Caucasian
Black or
African
0.00
75.00
14.57
26.98
American
Asian or
Pacific
0.00
20.00
4.71
7.63
Islander
Other or
0.00
10.00
3.14
3.72
unknown

Responses
7
7
7
7

B. Estimated distribution of Hispanic or Non-Hispanic stratification of ovarian cancer
patients.
Average
Standard
Answer
Min Value Max Value
Responses
Value
Deviation
NonHispanic
86.00
100.00
93.29
5.44
7
(any race)
Hispanic
0.00
14.00
6.86
5.52
7
(any race)
In response to the question as to whether ovarian cancer clinical trials are a priority at your own
particular practice site, nearly three-quarters of the nurses said they are not (Table 4.4).
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Table 4.4. Are clinical trials a priority at your practice site?
Yes
No
Total

2
5
7

29%
71%
100%

With regard to the outer setting, all practices said they have websites and are sometimes
mentioned in the newspaper or on local television. All seven practice nurses reported having a
collaborative relationship with another hospital for clinical trials; five named Moffitt Cancer
Center, one named Florida Hospital and Moffitt Cancer Center, and one named Tampa General.
Characteristics within the inner setting include provision of patient education materials, which all
seven practice sites provide with regard to treatment and symptoms, but less than three-fourths
provide for clinical trials and support groups (Table 4.5A).
When asked if the practice provides patient education literature on clinical trials (Table 4.5B),
however, the proportion of those that said yes exceeded the answer (71%) provided in the
preceding table, which may have been interpreted as oral discourse, which, logically would
make one expect a higher percentage in the previous rather than the subsequent table.
Table 4.5. Practices that provide patient education.
A. Education focused on treatment, symptoms, clinical trials, and/or support groups.
Treatment
7
100%
Symptoms
7
100%
Clinical trials
5
71%
Support groups
5
71%
B. Practices that provide patient education literature on clinical trials.
Yes
6
86%
No
1
14%
Total
7
100%
When asked if the practice has a plan for presenting the option of a clinical trial to women with
ovarian cancer, 57% responded that there is no plan (Table 4.6A).
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If a woman with ovarian cancer initiates a question about clinical trials, most nurses said she is
referred to the physician for further discussion (Table 4.6B).

Table 4.6. Nurses were asked questions about practice policy related to clinical trials.
A. Does the practice have a plan for presenting the option of a clinical trial to women
with ovarian cancer?
Yes
3
43%
No
4
57%
Total
7
100%
B. If a patient asks about clinical trials, is she referred to the doctor for further
discussion?
Yes
5
71%
No
2
29%
Total
7
100%
Nurses were also asked who is most likely to bring up the subject of clinical trials and most said
the physician (71%), followed by either the nurse practitioner or research nurse (each 14%),
with no one selecting the primary care nurses or the patient as being likely to bring up the
subject of a clinical trial (Table 4.7).
Table 4.7. When clinical trials are discussed, who is most likely to bring up the topic?
Physician
Nurse practitioner
Research nurse
Primary care nurse
Ovarian cancer patient

5
1
1
0
0

71%
14%
14%
0%
0%

The team members that nurses felt should be able to discuss clinical trials with the patient are
shown in Table 4.8; the physician was selected by all, then the nurse practitioner or research
nurse, with the primary care nurses being the least selected option.
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Table 4.8. Nurses were asked to specify which team member(s) they feel should be able to
discuss clinical trials. (They were asked to select all that apply.)
Physician
Nurse practitioner
Research nurse
Primary care nurse

7
6
6
5

100%
86%
86%
71%

Less than half of the practice nurses said they use clinical-trial matching websites; those that do
use them were asked to specify which sites they use, shown in Table 4.9.
Table 4.9. Nurses were asked if they ever use trial matching websites.
Yes.
If so, write the name(s) of the website(s) you find most helpful.
• NCI.gov http://www.cancer.gov/
• clinicaltrials.gov https://clinicaltrials.gov/
• FloridaCancerTrials http://floridacancertrials.com/en/
• Moffitt Cancer Center
https://moffitt.org/clinical-trialsresearch/?utm_source=Socius&utm_medium=BingCPC&utm_campaign=Socius
No
Total

3

43%

4
7

57%
100%

Although less than a third of the nurses reported that clinical trials are a priority in their practice,
more than half of the nurses responded that their practice does provide clinical-trial education to
staff (Table 4.10).
Table 4.10. Does your practice educate staff about clinical trials?
Yes
No
Total

4
3
7

57%
43%
100%

With regard to cost coverage of clinical trials, 86% of nurses reported that they believe health
insurance would cover standard-of-care costs in a clinical trial, while only 14% (one nurse)
believed that the Affordable Care Act would cover clinical trial costs (see Table 4.11 and 4.12).

55

Table 4.11. Clinical trials and insurance coverage.
Do you believe that health insurance covers standard-of-care costs in a clinical trial?
Yes
6
86%
No
1
14%
Total
7
100%
Table 4.12. Would the Affordable Care Act (ACA) would be helpful or unhelpful in covering
patients’ clinical trial costs?
Helpful (please
briefly explain why)
Unhelpful (please
briefly explain why)

May provide patients with better access to care

1 14%

I don’t know that it would cover clinical trials
Will limit what we can offer as SOC.
Standard of care is all that is typically covered
Many of the plans available have narrow networks thus not
providing coverage for clinical trials

6 86%

Nurses were asked about the timing of informing ovarian cancer patients about clinical trials
related to the time when they are diagnosed, and they were also asked if they thought clinical
trials should be the last resort after all standards of care have failed (see Tables 4.13). While
nearly three-quarters of the nurses thought patients should be informed about clinical trials right
after being diagnosed with ovarian cancer, 43% of the nurses felt clinical trials should be the last
resort after all known treatment have failed.
Table 4.13. Timing the discussion of clinical trials
A. Should ovarian cancer patients be informed about clinical trials right after being
diagnosed?
Yes
5
71%
No
2
29%
Total
7
100%
B. Should clinical trials be the last resort after all known treatments have failed?
Yes
3
43%
No
4
57%
Total
7
100%
More than half of the nurses stated that women with ovarian cancer sometimes ask about
clinical trials (Table 4.14), which conforms to their response in Table 4.7 that patients are least
likely to initiate discussion of trials; after a physician initiates trial discussion, the patient may
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share thoughts or questions with the nurse, who usually spends more time talking to and
educating patients.
Table 4.14. Do women with ovarian cancer ever ask you about clinical trials?
Yes
No
Total

4
3
7

57%
43%
100%

Nurses provided the following reasons women have given for not wanting to participate in an
ovarian cancer clinical trial:
•

Do not want treatment anymore (usually have been through multiple regimens)

•

Time involved for visits and treatment

•

Want to try interventions that are standard of care first

•

Afraid of the unknown

•

They want up-front therapy

•

Concern about lack of response

Most nurses (71%) said they are comfortable answering patients’ questions about clinical trials,
feel well-informed when patients ask about clinical trials, and have practice resources to help
them answer questions (Table 4.15).
Table 4.15. Questions asked nurses about feeling comfortable, well-informed, and having
accessible to resources when asked about clinical trials.
A. Are you comfortable answering patients’ questions about clinical trials?
Yes
5
71%
No
2
29%
Total
7
100%
B. Do you feel well-informed when patients ask about clinical trials?
Yes
5
No
2
Total
7
Table 4.15 continues on next page.
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71%
29%
100%

Table 4.15 (continued)
C. Does your practice have resources to help you answer questions about clinical
trials?
Yes
5
71%
No
2
29%
Total
7
100%

The practice resources that nurses listed include the telephone number for the clinical trial
nurse, being well-informed through training as a research nurse, having literature, and using
internet resources. Only 29% of nurses said that their practice team discusses ovarian cancer
clinical trials during team meetings (Table 4.16A).
Table 4.16. Practice information, desire for more knowledge, and practice team plans.
A. Does your practice discuss ovarian cancer clinical trials during team meetings?
Yes
2
29%
No
5
71%
Total
7
100%
B. Would you like to know more about clinical trials?
Yes
4
57%
No
3
43%
Total
7
100%
C. Does your team have a plan for offering clinical trials to women with recurrent or
persistent ovarian cancer?
Yes
4
57%
No
3
43%
Total
7
100%
D. If you do not have a clinical trial for a woman with ovarian cancer who wants one, do
you have a plan to help her find one?
Yes
5
71%
No
2
29%
Total
7
100%

Nurses were asked if they would like to know more about clinical trials, and more than
half said yes, while less than half said no (Table 4.16B). Asked if the practice has a plan for
offering clinical trials to women with recurrent or persistent ovarian cancer, more than half of the
nurses said yes, while less than half said no (Table 4.16C). Those who said yes were asked to
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elaborate on the plan, which included a referral to Moffitt, use of a clinical trial priority tree and
list of trials, and one who thought so but was uncertain of what the plan was.
While four of seven nurses said their team has a plan for offering clinical trials to women
with recurrent or persistent ovarian cancer (Table 4.16C), five nurses said that if they do not
have an on-site trial for a woman who desires a study, they have a plan to help her find one
(Table 4.16D). The five nurses who have a plan cited their plans as calling to set up an
appointment for the patient, searching for a trial themselves, referring to Moffitt or to a tertiary
center.

Nurses were asked to share final thoughts, which follow:
•
•
•
•

I have confidence in the trials at Moffitt and the patients that we have referred are always
pleased with the options and care
Need to have increased community awareness that trials are available; local oncologists
should refer sooner.
It would be great to have more information available to patient about clinical research.
We have a working relationship with Moffitt.

Women with Ovarian Cancer

As shown in Table 4.17, participants with ovarian cancer ranged in age from 28 to 79, with a
mean age of 64.1 (SD 12.29) and were 90% white and 10% black. Fourteen women (70%) were
married, three (15%) were divorced or separated, two (10%) were widowed, and one (5%) was
single. Twelve women (60%) reported that they were retired, three (15%) stated they were
unemployed, two (10%) said they work part time, and three (15%) stated they work full time.
Three women (15%) had stage IV disease, fourteen (70%) were stage III, one (5%) was stage
II, and two (10%) were stage I.

59

Table 4.17. Age, Race, marital and employment status, and stage of disease of participants
with ovarian cancer (N=20).
Age When Completing Survey
Mean
Std Dev
64.1
12.29

Range
28-79

Median
67

Race
White
18
90%

Black
2
10%

Married
14
70%

Marital Status
Divorced or separated
Widowed
3
2
15%
10%

Single
1
5%

Employed Full time
3
15%

Employment Status
Employed Part time
Retired
2
12
10%
60%

Unemployed
3
15%

Stages of Disease
I
2
10%

II
1
5%

III
14
70%

IV
3
15%

Participants were asked the following questions with regard to clinical trials:
1. Have you ever been in a clinical trial?
2. Would you consider a clinical trial if asked?
3. Have you ever been offered a trial but failed to meet the inclusion criteria?
4. Does your doctor have clinical trials?
5. Has your doctor or nurse ever discussed clinical trials with you?
6. Have you ever asked your doctor or nurse about clinical trials?
Nearly half of the participants (see Table 4.18) have never been in a clinical trial, yet 90% of the
women said they would consider a clinical trial if offered in the future; the two who would not
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Table 4.18. Women with ovarian cancer, past participation in clinical trials, intention to
participate in the future, and interaction with their physician (N=20).
Questions

Yes

No

9
18

% of
total
45%
90%

11
2

% of
total
55%
10%

Have you ever been in a clinical trial?
If you were offered a clinical trial in the near future,
would you\consider it?
Have you ever been offered a clinical trial then failed to
meet the\inclusion criteria?
Does your doctor offer clinical trials?
Has your doctor or nurse ever discussed clinical trials
with you?
Have you ever asked your doctor or nurse about clinical
trials?

4

20%

16

80%

9
13

45%
65%

11
7

55%
35%

13

65%

7

35%

consider a clinical trial stated their reasons, which follow:
•
•
•

I am a 12 year survivor and would most probably do traditional chemo, but would be
open to hearing my options.
At present time I am maintaining within normal range CA125 with alternative Ave'Ultra &
IMMPOWER capsules.

Four participants who wanted to participate in a clinical trial were unable to enroll because they
failed to meet the inclusion criteria; the following reasons for failing were provided by two of the
women:
•

My tissue from surgery didn't match what they needed.

•

—past resolved health issue unrelated to current illness but may be induced by trial
medication.

Thirteen women (65%) said their doctor or nurse had discussed clinical trials, while seven
women (35%) said provider discussion had never occurred. Thirteen women (65%, not the
same individuals) said they have asked their doctor or nurse about clinical trials, and seven
women (35%) have not (see Table 4.18).
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Women were asked if they think it makes sense to consider a clinical trial right after
being diagnosed with cancer, and more than half of the women said yes (see Table 4.19).
Those who said “no” were stages III and IV, while those who said “yes” included two women
with stage I disease and one woman with stage II disease, along with eight women who are
stage III and one who is stage IV.
Table 4.19. Does it make sense to consider a clinical trial right after being diagnosed with
ovarian cancer? (N=20).
All Stages Combined
Yes
12
60%
No

8

40%

Stage I
2 (17% of
“Yes”)
0

Stage II
1 (<1% of
“Yes”)
0

Stage III
8 (67% of
“Yes”
6 (75% of
“No”)

Stage IV
1 (<1% of
“Yes”)
2 (25% of
“No”)

Reasons given by the women who said clinical trials should not be considered right after being
diagnosed follow.
•

Cutting edge treatment (stage III)

•

Because hopefully the standard treatment will work for you. I won't consider clinical trials
unless standard treatment didn't work right away. (stage III)

•

Try standard treatment first (stage III)

•

Would want to try standard care treatment first (stage III)

•

They used stronger chem[otherapy;] clinical trial was not brought up. (stage III)

•

You need to do as your oncologist suggests so you know you are getting treatment and
in clinical trials you don't know. (stage III)

•

Should start off with standard of care. (stage IV)

•

Too much information all at once. Need some time to handle diagnosis before making
decisions. Need time to investigate standard protocols before looking into trials. (stage
IV)
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Most of the women said that it does make sense to consider clinical trials early upon being
diagnosed, and eleven of the twelve women provided their rationale, which follows.
•

Only the "gold standard" of treatment was prescribed and then changed to a stronger
chemotherapy due to my cell type. Options were not discussed. (stage I)

•

Many women do not realize that clinical trials should not just be considered at end of
treatment, but at diagnosis. (stage I)

•

I would like to stay proactive (stage III)

•

Cutting edge treatment (stage III)

•

To help beat cancer. (stage III)

•

I would say yes if I had no other options, but so far I have had other options. (stage III)

•

Keep all options open (stage III)

•

To save another. (stage III)

•

If it will address the cancer appropriately. (stage III)

•

Some treatment interfere with clinical trials (stage III)

•

You may very likely be given a very new promising drug that could greatly impact your
survival. (stage IV)

Women were asked if they felt their health insurance covers standard-of-care costs in a clinical
trial, and whether they thought the Affordable Care Act would be helpful in contributing to clinical
trial participation (Table 4.20).
Table 4.20. Women’s perceptions about clinical trial cost coverage by health insurance and the
Affordable Care Act.
Do you believe that health insurance covers
standard-of-care costs in a clinical trial? (Q35)
Do you think the ACA will be helpful in covering
CT costs? (Q36)
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86% Yes 14% No
14% Yes 86% No

QCA Analysis
The outcome of interest was enrollment in clinical trials by women with ovarian cancer. The
influents of enrollment were sought for two populations: women with ovarian cancer and nurses
in medical or gynecologic oncology practices. The influents were considered within the domains
of the Consolidated Framework for Implementation Research (CFIR), introduced and explained
in earlier chapters.
Consistency for crisp sets is the percentage of cases in each row displaying the
outcome. Consistency scores of either 1 or 0 indicate perfect consistency for a given row, while
a score of 0.50 indicates perfect inconsistency. When evaluating possible necessary conditions,
rows with consistency of ≥ 75% should be coded 1 for the presence of the outcome variable,
while those below 75% should be coded 0 for absence of the outcome variable (personal
communication with Dr. Charles Ragin on September 14, 2015). "Coverage" is the percentage
out of all observations that exhibit that implication or inference, and "consistency" is the
percentage of observations conforming to that combination of variables having that particular
value of the dependent variable or outcome, which are calculated and reported.
Patients
QCA analysis is an iterative process with multiple variables that may contribute to the
cause of an outcome. If too many conditions are used, it may be more difficult to drill down to
the key factors, thus if there are similar conditions, those that are related can be consolidated
into one. For example, instead of including a separate condition for each team member within
the clinical practice (e.g., physician, nurse, nurse practitioner), it can be advantageous to
combine each team member into one condition that means any practice team member
discussed the issue. Table 4.21 is a matrix for the outcome of enrolling in a clinical trial. In the
table, in the second column, there is a 1 for presence of the condition and a 0 for absence of the
condition. The labels A to F, at top right in the table, are explained in the last row. Each
represents a condition felt to be a cause of enrollment in a clinical trial.
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Table 4.21. Data matrix of conditions considered for inclusion in QCA.
Set membership

Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
Was not in a CT
A = CT available
D = Any suggest

Outcome (1 means
Conditions (1 = Present and 0 = Absent)
participation is
A
B
C
D
E
F
present; 0 means
participation is absent)
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
0
0
0
1
1
0
1
1
0
0
1
1
0
1
1
0
0
1
1
0
1
0
1
1
0
1
0
1
1
0
1
1
1
0
1
0
0
0
1
1
0
1
1
0
0
0
1
0
1
1
1
1
1
1
0
1
1
0
0
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
B = Stage III/IV
C = We discuss
E = Want information F = Family supports

Women with Ovarian Cancer
Table 4.22 is a truth table for the hypothesized potential conditional configurations. In the nextto-last column is the number of cases that were included in each configuration. Raw consistency
is the percentage of the number of cases that were actually in the configuration of conditions.
The revised truth table contains less conditions in the hope of deriving a higher consistency
score before running the analysis. Cases in Table 4.23 with consistency below 75% were coded
0, while cases with consistency of at least 75% were coded 1. Remainder rows, which have no
cases in them, were deleted.
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Table 4.22. Truth Table of Hypothesized Potential Conditional Configurations
Row

CT
available

st3or4

wediscuss

anysugg

wantinfo

famsupp

i.
ii.
iii.
iv.
v.
vi.
vii.

1
1
1
1
1
1
1

1
1
0
1
1
1
0

1
0
0
1
0
0
1

1
0
0
0
1
0
1

1
1
1
1
1
0
0

1
1
1
1
1
1
1

Number of
cases in
configuration
11
3
2
1
1
1
1

Raw
consistency
0.818182
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000

Table 4.23. Revised Truth Table.
Row

Stage 3 or 4

wediscuss

Wantinfo

i.
ii.
iii.
iv.
v.

1
1
0
1
1

1
0
0
0
1

1
1
1
0
0

Number of
cases in
configuration
12
4
2
1
1

Raw
consistency
0.833333
0.000000
0.000000
0.000000
0.000000

Table 4.24 shows the QCA solutions and consistency and coverage for women enrolled (and
not enrolled) in clinical trials. Coverage is the portion out of all observations that reflect the
inference. Consistency is the portion of observations that conform to that combination of
variables having that particular value of the dependent variable. The desire to achieve perfect
coverage and consistency values of 1, if possible, required another combination of variables,
shown in the following truth table (see 4.25). Because acceptance of consistency below .80 is
not recommended, this combination of conditions was not pursued. The best result with the
highest consistency and coverage scores is the condition cluster in tables 4.23 and 4.24.
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Table 4.24. QCA Solutions, Consistency and Coverage for women enrolled in clinical trials and
women not enrolled in clinical trials.
Outcome

Enrolled
in CTs

NOT
Enrolled
in CTs

Complex (solution
coverage:1;solution
consistency:
0.83333)
Parsimonious
(solution
coverage:1;solution
consistency:
0.83333)
Intermediate
(solution
coverage:1;solution
consistency:
0.83333)
Complex
(solution coverage:
0.8 and solution
consistency:1.0)
Parsimonious
(solution coverage:
0.8 and solution
consistency:1.0)
Intermediate
(solution coverage:
0.8 and solution
consistency:1.0)

Solutions

Consistency

Raw
Coverage

Unique
Coverage

st3or4*wediscuss*wantinfo

0.83333

1.0

1.0

st3or4*wediscuss

0.83333

1.0

0.0

wantinfo*wediscuss*st3or4

0.83333

1.0

1.0

st3or4*~wediscuss
~wediscuss*wantinfo
~st3or4*wediscuss*~wantinfo

1.0
1.0
1.0

0.5
0.6
0.1

0.1
0.2
0.1

~wediscuss
~wantinfo
~st3or4

1.0
1.0
1.0

0.7
0.2
0.3

0.4
0.0
0.0

wantinfo* ~wediscuss
~wediscuss*st3or4
~wantinfo*wediscuss*~st3or4

1.0
1.0
1.0

0.6
0.5
0.1

0.2
0.1
0.1

*wantinfo

Table 4.25. Truth Table Combination with Consistency Score Below 0.80
Row
i.
ii.
iii.
iv.

anysug
gdisc
1
0
0
1

st3or4

wantinfo

famsupp

1
1
0
0

1
1
1
0

1
1
1
1

Number of cases in
configuration
13
3
2
1

Raw
consistency
0.769231
0.000000
0.000000
0.000000

An attempt was made to introduce another variable associated with women who did not
participate in clinical trials and the possible influence of preference for standard of care. Of
eleven women who were not in a clinical trial, only five clarified their preference for the standard
of care, thus consideration of that variable did not produce a viable solution.
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Setting the dependent variable as clinical trial enrollment with several combinations of
variables yielded no considerable consistency or coverage for a crisp set analysis. A necessity
analysis, which does not produce a truth table, was conducted using nonparticipation in a trial
and preference for standard of care and presence or absence of provider discussion (see Table
4.26). A perfect solution was not reached because interviews would be necessary to determine
preference for standard of care by all eleven of the nonparticipants. The analysis below is
saying that there is a correlation between not participating and preferring the standard of care
while having no provider discussion, and that the opposite is true for participants. Again, it is not
a perfect solution because interviews would be needed to clarify missing information for the
conditions tested.
Table 4.26. Necessity Analysis for Trial Participation Considering Preference for Standard of
Care and Provider Discussion
Outcome variable
~partct
partct

Conditions Tested
prefers soc+~provdisc
~prefers soc+provdisc

Consistency
0.727273
1.000000

Coverage
1.000000
0.600000

Practice Nurses
Only seven nurses responded to the survey, making the use of QCA challenging. Nevertheless,
it was interesting to explore nurses’ feelings about which practice team members should be able
to discuss clinical trials with patients. We see a raw consistency of 1 in all combinations
because everyone in each combination is represented. There is nothing notable in this
information because the sample is very small and all of the nurses were closely affiliated with
tertiary care centers.
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Table 4.27. Truth Table for Nurses regarding practice team members who should be
communicating information on clinical trials.
Row

Physician

Nurse
practitioner

Primary
nurse

Research
nurse

i.
ii.
iii.

1
1
1

1
1
0

1
0
0

1
1
0

Number of
cases in
configuration
5
1
1

Raw
consistency
1.0
1.0
1.0

In the following truth table (Table 4.28), the intent was to see if those who have a plan for
offering clinical trials to women with ovarian cancer feel informed and are comfortable with
requests for information.
Table 4.28. Truth Table for nurses in practices that have a plan to help find trials, and its impact
on feeling informed and being comfortable with questions.
Row

comfquest

feelinformed

i.
ii.

1
0

1
0

Number of cases in
configuration
5
2

Raw consistency
0.8
0.5

The intermediate solution for this condition set follows. The small sample size prevents one from
drawing conclusions, but most of the observations for this pattern within the small sample felt
informed and were comfortable answering patients’ questions when the practice team had a
definitive plan.
Table 4.29. Truth Table Analysis for the impact of having a plan on feeling informed and being
comfortable with questions.
feelinformed*comfquest

coverage
0.800000

consistency
0.800000

Few causality patterns could be found within the nursing group because of the small sample
size and wide variation within that small group.
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Results by Study Population for the Research Questions
This exploratory multiple case study looked at factors within the domains of the
Consolidated Framework for Implementation Research (CFIR) associated within enrollment in
clinical trials. The factors were based on data from two populations: women with ovarian cancer,
and nurses in gynecologic and medical oncology practices. There is no existing definitive
process across cancer centers and oncology practices, some of which do not offer any ovarian
cancer clinical trials. A definitive process between/among institutions does not exist, thus
making the search for sufficient conditions associated with enrollment in clinical trials
challenging. The focus thus was on necessary conditions. The research questions follow:
1. What necessary and/or sufficient factors, based on Qualitative Comparative
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in
a clinical trial?
2. What barriers and facilitators exist with regard to enrolling women with ovarian
cancer in clinical trials?
Women with Ovarian Cancer
Research Question 1. Despite multiple attempts to try numerous iterative factor
combinations, the investigator was unable to achieve a perfect solution of 1.0 for coverage and
1.0 for consistency. The highest consistency (1.0) and coverage (0.83) for women who have
been in clinical trials was that they were stage III/IV, wanted information, and engaged in
discussion about clinical trials, making those factors necessary for enrollment in a study. The
reason that consistency may not have achieved 1.0 is that one of the patients had participated
in arthritis clinical trials and may not have participated in an ovarian cancer treatment study, and
she was not able to be reached by telephone for clarification. Another unique condition existed
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with a woman who said neither her nurse nor physician had suggested a trial, but she had
participated in one; she thus may have proactively sought one on her own.
With regard to intentions or willingness to consider a clinical trial, some women said they
would not participate because they were currently in treatment, thus it was unclear whether they
would pursue a clinical trial if they were not in treatment or were in treatment that failed to
stabilize or diminish their cancer.
Early stage patients who were cured of ovarian cancer were amenable to considering
clinical trials, but no conclusion can be drawn for that very small subset of three early stage (I/II)
patients who consented to this study. Women with early and later stage ovarian cancer,
however, all stated a desire for information on clinical trials, and all believe their family members
would support them if they participated in a clinical trial. Women indicated that they hear about
and discuss clinical trials mostly with their physician; for many physicians, however, including
some who are affiliated with institutions that offer clinical trials, clinical studies are not a priority.
Women are not always aware that recurrent cancer is terminal, or that the “gold standard” is not
synonymous with a cure.
Research Question 2. What barriers and facilitators, practitioner and patient-specific,
exist with regard to enrolling women with ovarian cancer in clinical trials?
Facilitators are contributors to being in a clinical trial, expressed by at least 50% of those
who have been in a clinical trial. Barriers impede participation; in Table 4.30, below, the scores
with the greatest discrepancies between those who have been in a clinical trial and those who
have not, suggest obstacles to being in a clinical trial.
The data thus suggests that discussion with the provider of care, to some extent the
existence of patient-accessible clinical trial literature in the practice, knowledge that health
insurance covers standard of care costs, and the provider offering clinical trials are facilitators
for participation. Absence of those factors thus constitutes a barrier.
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Table 4.30. Factors for women who have and have not been in clinical trials, suggesting facilitators
and barriers, are compared. A facilitator is a factor that is true for at least half of the women who
participated in clinical trials. A barrier is a factor for which there is a difference of at least 20
percentage points. Widely discrepant scores suggest that awareness that facilitated participation for
some women, when misperceived, is a barrier to participation for other women. Also included, for
interest in the population of women who have not been in a clinical trial, is the question on intention
(third column from left) to be in a clinical trial and its relationship to intention to use a trial matching
tool, should one exist (fourth column from right).
Participated in at
least 1 CT

9
100%
Did not
participate
in a CT

11
100%

Your
provider
has discussed
CTs with
you
(1yes,
0no)

If offered
a CT, you
would
consider
it (1yes,
0no)

You have
seen patient
education
literature on
CTs in your
provider's
office.
(1yes, 0no)

It makes
sense to
consider a
CT soon
after you are
diagnosed.
(1yes, 0no)

You do
not
believe
CTs are
an option
only after
SOC
fails.
(1yes,
0no)

If your
oncologist
had a
website
trialmatching
tool, you
would use it.
(1yes, 0no)

Health
insurance
would cover
the
standard of
care costs
involved in
a CT. (1yes,
0no)

The ACA
would be
helpful in
supporting CT
costs.
(1yes,
0no)

Your
provider
offers
CTs

9
100%

8
89%

6
67%

5
56%

6
67%

7
78%

8
89%

5
56%

7
78%

Your
provider
has discussed
CTs with
you
(1yes,
0no)

If offered
a CT, you
would
consider
it (1yes,
0no)

You have
seen patient
education
literature on
CTs in your
provider's
office.
(1yes, 0no)

It makes
sense to
consider a
CT soon
after you are
diagnosed.
(1yes, 0no)

If your
oncologist
had a
website
trialmatching
tool, you
would use it.
(1yes, 0no)

Health
insurance
would cover
the
standard of
care costs
involved in
a CT. (1yes,
0no)

The ACA
would be
helpful in
supporting CT
costs.
(1yes,
0no)

Your
provider
offers
CTs

4

10

3

7

You do
not
believe
CTs are
an option
only after
SOC
fails.
(1yes,
0no)
7

10

6

6

2

36%

91%

27%

64%

64%

91%

55%

55%

18%

Practice Nurses
Research Question 1. As previously explained, the small sample of nurses (7) was not
conducive to yielding a combination of conditions with coverage and consistency of 1.0. The
highest coverage and consistency were 0.8, for the impact of having a practice team plan
related to enrolling women with ovarian cancer in clinical trials, resulting in nurses feeling
informed and comfortable with questions women might ask about trials. Numerous combinations
of conditions were tried, and nothing else resulted in coverage and consistency that exceeded
0.75.
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Research Question 2. What barriers and facilitators, practitioner and patient
specific, exist with regard to enrolling women with ovarian cancer in clinical trials?
More clinical-trial enrolling-referring nurses have a practice team plan (67% versus 25%, in
Table 4.31 below), suggesting that having a plan is a facilitator and not having one is a barrier.

Table 4.31. Factors for nurses who have and have not enrolled or referred at least one woman
to a facility for enrollment in a clinical trial are compared. A facilitator is a factor that is true for
≥50% of practice nurses. A barrier is a factor for which there is a difference of ≥ 20%.
Enrolled
or
referred
at least 1
woman
for a CT

OvCa
CTs are
a
practice
priority
(1yes,
0no)

Your
practice
or clinic
educate
s staff
on CTs
(1yes,
0no)

You feel
well
informed
and
comfortabl
e when a
patient
asks about
clinical
trials.
(1yes, 0no)

Your
practice
has a plan
for
presentin
g the CT
option to
women
with ovca
(1yes,
0no)

You
believe
health
insuranc
e covers
standard
of care
costs for
CTs?
(1yes,
0no)

You
believe
the ACA
will be
helpful (1)
or
unhelpful
(0) in
supportin
g CT
costs.

CTs
should
be the
last
resort
after
SOC
Tx
fails
(1yes,
0no)

1
1
1
3

0
1
0
1
33%
OvCa
CTs are
a
practice
priority
(1yes,
0no)

1
0
1
2
67%

1
1
0
2
67%
You feel
well
informed
and
comfortable
when a
patient asks
about
clinical
trials. (1yes,
0no)

0
1
1
2
67%

1
1
1
3
100%

0
0
1
1
33%

Your
practice
has a plan
for
presentin
g the CT
option to
women
with ovca
(1yes,
0no)

You
believe
health
insuranc
e covers
standard
of care
costs for
CTs?
(1yes,
0no)

You
believe
the ACA
will be
helpful (1)
or
unhelpful
(0) in
supportin
g CT
costs.

1
0
0
1
33%
CTs
shoul
d be
the
last
resort
after
SOC
Tx
fails
(1yes,
0no)

1
0
1
1
3
75%

0
0
0
1
1
25%

1
1
1
0
3
75%

0
0
0
0
0
0%

Did not
enroll or
refer any
women
for a CT

0
0
0
0
4
0%

0
0
0
1
1
25%

Your
practice
or clinic
educates
staff on
CTs
(1yes,
0no)

0
0
1
1
2
50%
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1
0
1
0
2
50%

Women
with ovca
should be
informed
about
CTs as
soon as
possible
after
being
diagnose
d (1yes,
0no)
1
1
1
3
100%
Women
with ovca
should be
informed
about
CTs as
soon as
possible
after
being
diagnose
d (1yes,
0no)
0
0
1
1
2
50%

Women
with ovca
sometime
s ask you
about
CTs.

1
1
1
3
100%
Women
with ovca
sometime
s ask you
about
CTs.

1
0
0
0
1
25%

Additional facilitators are recognition that health insurance covers standard of care costs,
and that the ACA supports clinical trial costs. While not quite reaching a 20% difference, the
perception that clinical trials should be the last resort after the standard of care has failed is
likely impeding eligibility because of limits on maximum prior regimens as well as having poor
ECOG scores associated with complications of advanced disease. The belief that women
should be informed about clinical trials as early as possible after diagnosis is a facilitator;
absence of that belief is thus a barrier to enrollment. The fact that women bring up the
discussion about clinical trials to enrollers may be related to the population that seeks care at
facilities that offer clinical trials; regardless, it suggests that women would do well to ask the
question, which, if no trials are offered on site, may result in a referral. Table 4.18 suggests that
practice resources could be used to improve knowledge and comfort levels among all nurses. .
Relating Results to the Theoretical Model
A review of survey results identified opportunities for improvement in the outer and inner
settings, and with regard to individuals and the overall process. The conditions and scores that
represent opportunities for improvement are shown in bold font in the following tables for
practices (Table 4.32) and for women with ovarian cancer (Table 4.33). The tables are followed
by composite illustrations of the items that can be improved within each level of the
Consolidated Framework for Implementation Research (CFIR) framework. Figure 4.1
juxtaposes practice findings within the CFIR levels; descriptive statistical findings are red, while
QCA findings are purple. Figure 4.2 illustrates CFIR in which the findings of women with ovarian
cancer have been inserted, teal indicating descriptive statistics, and purple indicating QCA
findings. The results in the tables and figures are discussed in chapter five.
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Table 4.32. Practice Scores for Descriptive Statistics that Indicate Opportunities for
Improvement within the Theoretical Framework.

•
•

•

•

•

Outer Setting: Public and Professional Resources
100% have a website.
Does your practice
have a website? (Q22)
71% Yes; 29% No and 0 computers for patients
Does your practice
have clinical trial
resources for
patients? (Q47)
86% Yes; 14% No
Does your practice
provide patient
education literature on
clinical trials? (Q31)
57% Yes; 43% No
Does your practice
educate staff about
clinical trials? (Q34)
71% Yes
Does your practice
have resources to help
you answer questions
about clinical trials?
(Q43)

Inner Setting
Networks/Communication
When ovarian cancer clinical trials are discussed with patients, who is most likely to bring up the
topic? (Q28)
5
• The physician
1
• Research nurse
1
• Nurse practitioner
0
• The patient
0
• Primary care nurse
Does your practice provide ovarian cancer patient education on any of the following? (Q23)
7
• Treatment
7
• Symptoms
5
• Clinical trials
Which of the following should be able to talk about ovarian cancer clinical trials with patients?
(Q29)
7
• Physicians
6
• Nurse practitioners
6
• Research nurses
5
• Primary care nurses
Do you ever use clinical trial websites? (Q32)
43% Yes 57% No
Does your team discuss ovarian cancer clinical trials during team
meetings? (Q46)
Table 4.32 continues on next page.
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29% Yes

71% No

Table 4.32 (continued)
When ovarian cancer clinical trials are discussed with patients, who is most likely to bring up the
topic? (Q28)
5
• The physician
1
• Research nurse
1
• Nurse practitioner
0
• The patient
0
• Primary care nurse
Does your practice provide ovarian cancer patient education on any of the following? (Q23)
7
• Treatment
7
• Symptoms
5
• Clinical trials
5
• Support groups
Which of the following should be able to talk about ovarian cancer clinical trials with
patients? (Q29)
7
• Physicians
6
• Nurse practitioner
6
• Research nurses
5
• Primary care nurses
Do you ever use clinical trial websites? (Q32)
43% Yes 57% No
Does your team discuss ovarian cancer clinical trials during team
29% Yes 71% No
meetings? (Q46)
If a patient asks about clinical trials, is she referred to the doctor for 71% Yes 29% No
further discussion? (Q48)
Implementation and Learning Climate
Do you think ovarian cancer clinical trials are a priority at your
facility? (Q30)
Do you have computers in the waiting area for patients’ use? (Q33)
Do you ever use clinical trial websites? (Q32)
Does your practice provide patient education literature on clinical
trials? (Q31)
Does your practice educate staff about clinical trials? (Q34)
Does your practice have resources to help you answer questions
about clinical trials? (Q43)
Do you think ovarian cancer clinical trials are a priority at your
facility? (Q30)
Do you have computers in the waiting area for patients’ use? (Q33)
Do you ever use clinical trial websites? (Q32)
Does your practice provide patient education literature on clinical
trials? (Q31)
Does your practice educate staff about clinical trials? (Q34)
Does your practice have resources to help you answer questions
about clinical trials? (Q43)
Table 4.32 continues on next page.
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29% Yes 71% No
0% Yes 100% No
43% Yes 57% No
86% Yes 14% No
57% Yes 43% No
71% Yes 29% No
29% Yes 71% No
0% Yes 100% No
43% Yes 57% No
86% Yes 14% No
57% Yes 43% No
71% Yes 29% No

Table 4.32 (continued)
Individual Level
Do you believe that health insurance covers standard-of-care costs
in a clinical trial? (Q35)
Do you think the ACA will be helpful in covering CT costs? (Q36)
Do you want to know more about clinical trials? (Q44)
Should ovarian cancer patients be informed about clinical trials as
early as possible after being diagnosed? (Q37)
Should clinical trials be the last resort after all known treatments
fail? (Q38)
Are you comfortable answering patients’ questions about clinical
trials? (Q41)
Do you feel well informed when patients ask about clinical trials?
(Q42)
Process Planning, Engaging, Executing
Does your team have a plan for offering clinical trials to women with
recurrent or persistent ovarian cancer? (Q45)
If you don’t have a clinical trial for a woman with ovarian cancer who
wants one, do you have a plan to help her find one? (Q49)

86% Yes 14% No
14% Yes 86% No
57% Yes 43% No
71% Yes 29% No
43% Yes 57% No
71% Yes 29% No
71% Yes 29% No
57% Yes 43% No
71% Yes 29% No

Legend: Red = descriptive statistics Purple = QCA results
Figure 4.1. Translating Practice Findings to Opportunities within the Consolidated Framework
for Implementation Research (CFIR)
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Table 4.33. Patients’ Scores for Descriptive Statistics that Indicate Opportunities for
Improvement within the Theoretical Framework.
Inner Setting
Structural Characteristics for Women with Ovarian Cancer
Yes
%
No
%
Has your doctor or nurse ever discussed clinical trials with you?
13
65%
7
35%
(Q8)
Does your oncologist offer clinical trials? (Q14)
9
45%
11
55%
Networks/Communication Culture
Which of the following providers of care have ever suggested you think about a clinical trial?
Check all that apply (Q13)
c Oncologist
12
c Family member
5
c Friend
5
c Nurse practitioner
3
c Research nurse
0
c Primary care nurse
1
Do you think website information for any of the following topics is helpful? Check all that apply
(Q28)
c Treatment
19
c Clinical trials
19
c Symptoms
18
c Support groups
15
Yes
%
No
%
If you wanted a clinical trial that your practice didn’t offer, do you
think your doctor would help you find a facility that offers the
18
90%
2
10%
trial? (Q22)
Implementation, Incentives, Learning Climate

Yes

%

No

%

9

45%

11

55%

14

70%

6

30%

17

85%

3

15%

Individual Behavior, Intention, Knowledge, Beliefs, Self-Efficacy

Yes

%

No

%

Have you ever been in a clinical trial? (Q10)
Have you ever asked your doctor or nurse about clinical trials?
(Q9)
If you were offered a clinical trial in the near future, would
you\consider it? (Q11)
Do you believe that health insurance covers standard-of-care
costs in a clinical trial? (Q29)
Do you think the ACA will be helpful in covering CT costs? (Q30)
If your doctor or nurse mentions clinical trials, do you want to
know more? (Q15)
Do you think it makes sense to consider a clinical trial right after
you are diagnosed with cancer? (Q18)
Do you think clinical trials are an option to be considered only if
other treatments stop working? (Q19)
Table 4.33 continues on next page.

9

45%

11

55%

13

65%

7

35%

18

90%

2

10%

14

70%

6

30%

11

55%

9

50%

18

90%

2

10%

12

60%

8

40%

7

35%

13

65%

Have you ever seen patient education literature on clinical trials
in your doctor’s office? (Q17)
Does your oncologist have a website? (Q26)
If your oncologist had a website that helped you find matching
clinical trials, would you use it? (Q27)
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Table 4.33 (continued)
Individual Behavior, Intention, Knowledge, Beliefs, Self-Efficacy
(continued)
Are you comfortable answering bringing up the subject of clinical
trials to your doctor? (Q16)
If a clinical trial required extra visits, would that stop you from
participating? (Q23)
If a clinical trial meant traveling an extra 30 miles each visit,
would that stop you from participating? (Q24)
Would your family be supportive if you were in a clinical trial?
(Q25)

Yes

%

No

%

19

95%

1

5%

0

0%

20

100%

0

0%

20

100%

20

100%

0

0%

Legend: Teal = descriptive statistics Purple = QCA results
Figure 4.2. Translating Patients’ Findings to Opportunities within the Consolidated Framework
for Implementation Research (CFIR)

The next chapter discusses facilitators and barriers, and the challenges, strengths, and
weaknesses associated with this study.
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CHAPTER FIVE: DISCUSSION AND CONCLUSIONS
The Need for the Study
This study was done because ovarian cancer will lead to 14,180 deaths and 21,290 new
diagnoses in 2015 (ACS, 2015) and is the most lethal gynecologic cancer, with a
disproportionately high ratio of deaths to initial diagnoses. Ovarian cancer has had a relatively
stable mortality rate since 1975 (NCI, 2013), despite a decrease in mortality for all gynecologic
cancers combined. The disease is usually diagnosed at advanced stages, when, for most
women, the disease will not be curable. Despite the existing National Comprehensive Cancer
Network (NCCN) guideline that women with persistent or recurrent ovarian cancer should be
offered a clinical trial as a treatment option along with the standard-of-care (SOC) regimen, few
women with persistent or recurrent ovarian cancer are offered or enrolled in clinical trials. There
were no studies on clinical trial barriers and facilitators that focused on women with ovarian
cancer, thus indicating a need for a multiple case study to obtain information for this population.
Ovarian cancer compromises quality of life for women who are diagnosed with the
disease, many of whom undergo initial and interval debulking surgery and multiple lines of
cytotoxic chemotherapies that can cause adverse effects. Women who were employed may
become disabled, and the impact of the disease will thus reverberate within the family,
introducing the need for caregiving by family members. The disease burden includes healthcare costs, adding the expense of copays and significant costs associated with complex surgery
and multiple regimens of chemotherapy. The average annual cost of care for an ovarian cancer
patient, 65 or older, is $82,324 for initial treatment and $8,296 for continuing care; care in the
last year of life, if death is the direct result of ovarian cancer, is projected to cost $99,715,
versus $12,257 if death results from something other than ovarian cancer (Mariotto, Yabroff,
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Feuer, & Brown, 2011). The standard of care can improve only via the clinical trial process, and
yet the rarity of ovarian cancer makes adequate accrual numbers for statistical power difficult to
achieve. It is thus especially important that regional, statewide, and national accrual-promoting
network strategies be developed and shared to increase opportunities for women with advanced
disease to enroll in clinical trials.
Implications for Public Health
The public health system includes “all public, private, and voluntary entities that
contribute to the delivery of essential public health services within a jurisdiction (CDC, 2014).”
This concept ensures that all entities’ contributions to the health and well-being of the
community or state are recognized in assessing the provision of public health services. The
three core functions of public health are assessment, policy development, and assurance, and
the ten essential environmental health services align with the three core functions, as shown in
the illustration below. Within assessment, responsible entities should monitor health and diagnose

Figure 5.1. The CDC’s 10 essential services within the 3 core functions of Public
Health, obtained via http://www.cdc.gov/nphpsp/essentialservices.html (CDC, 2014).
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and investigate health problems. Policy development should ensure that people are informed,
educated, and empowered, that responsible organizations mobilize community partnerships,
develop policies and enforce laws. Assurance must link people with providers of care in facilities
staffed a competent workforce, for whom effectiveness, access, and quality are measurable, and is
reinforced by research for new insights and innovative solutions (CDC, 2014).
Physicians who see women prior and up to their diagnosis may be unaware of the NCCN
guideline that states a woman with recurrent or persistent ovarian cancer should be offered both the
standard of care and/or a clinical trial. They all not to be blamed for lack of awareness; rather, the
need for awareness of the NCCN guideline should be supported by continuing education resources.
All providers and practices should be aware of the NCCN guideline and do their best to uphold it,
even if they must refer the patient out of network to another practice or facility that has a suitable
clinical trial.
Initiatives should promote practice partnerships and referral networks that make information
on and access to clinical trials more prevalent. A strategy that rewards referring physicians and
encourages the patient’s return to the referring physician for care might stimulate more referrals to
centers that offer clinical trials. Assurance that women with recurrent or advanced ovarian cancer
are offered, per the NCCN guideline, either the standard of or a clinical trial can be realized only
through the provision of multidisciplinary provider education that is delivered with regularity to all
members of the practice team.

Implications for Practice
Women with Ovarian Cancer
The Tampa Bay area has Florida’s only NCI-designated comprehensive cancer center,
Moffitt Cancer Center; in addition there are other hospitals within the Florida Cancer Specialist
network that offer clinical trials. Despite having some of the best resources in the Tampa Bay
area, there are knowledge deficits and misperceptions in practice and among patients that
interfere with adherence to the NCCN guideline for women with persistent or recurrent ovarian
82

cancer. Women in rural regions of Florida presumably not only have misperceptions, but also
limited access as shown in Figure 2.4 in Chapter 2. Figure 2.4 indicated that as of 2013/14,
there were only 13 gynecologic oncologists in the upper third of Florida, compared to 33 in
central Florida and 39 in the southern third of the state.
The NCCN guideline should be shared more prominently in the public arena, enabling a
woman with recurrent or advanced ovarian cancer to ask her oncologist if she or he can offer or
help find a clinical trial, enabling her to make an informed decision about whether to pursue a
study or the standard of care. Women need tools for proactive discussions with oncologists and
skills to increase comfort in asking about options and the rationale for decisions about care.
Tools might include web-based trial-matching tools, sample lists of questions to ask physicians,
and how to have dialog that results in substantive replies over a simple yes or no.
Oncology Practices
There is a need for education for all disciplines within the practice: physicians, physician
assistants and nurse practitioners, and clinic nurses. Education should focus not only on
knowledge of the NCCN guideline, but also on skills on how to discuss, refer, and help women
find ovarian cancer clinical trials. Informing women on ovarian cancer clinical trials should not
begin after treatment fails, but as early as possible after the diagnosis to enable them to take
advantage of studies on biomarker-based agents, remission-sustaining agents, and studies
exploring novel dosing regimens and/or drug combinations. Practices should have visible
resources that can serve as cues for the patient to begin dialog about clinical trials. To stimulate
referrals for clinical trials, it is critical to implement partnerships and strategies that reward
referring oncologists, whether by sharing remuneration or some type of credit. The strategies
should engage the referring physician in the patient’s status and/or progress during the trial,
ideally by means of expedient shared electronic medical records. The principle investigator of
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the clinical trial should encourage the patient to seek non-trial-related care from the referring
physician.
Discussion and Conclusions
This multiple case study attempted to answer the following research questions:
1. What necessary and/or sufficient factors, based on Qualitative Comparative
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in
a clinical trial?
2. What barriers and facilitators exist with regard to enrolling women with ovarian
cancer in clinical trials?
Women with Ovarian Cancer
Research Question 1. This exploratory multiple case study looked at factors within the
domains of the Consolidated Framework for Implementation Research (CFIR) associated within
enrollment in clinical trials. Data was obtained from two populations: women with ovarian
cancer, and nurses in gynecologic and medical oncology practices.
There is no existing definitive clinical-trial enrollment process across cancer centers and
oncology practices, some of which do not offer any ovarian cancer clinical trials. A definitive
process between/among institutions might have made the search for sufficient conditions
associated with enrollment in clinical trials less challenging. The focus of this exploratory
multiple case study was thus was on necessary conditions.
Despite multiple attempts to try numerous iterative factor combinations, the investigator
was unable to achieve a perfect solution of 1.0 for coverage and 1.0 for consistency. The
highest consistency (1.0) and coverage (0.83) for women who have been in clinical trials was
that they were stage III/IV, wanted information, and engaged in discussion about clinical trials,
making those factors necessary for enrollment in a study. The reason that coverage may not
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have achieved 1.0 is that one of the patients had participated in arthritis clinical trials and may
not have participated in an ovarian cancer treatment study, and she was not able to be reached
by telephone for clarification. Another unique condition existed with a woman who said neither
her nurse nor physician had suggested a trial, but she had participated in one; she thus may
have proactively sought one on her own. With regard to intentions or willingness to consider a
clinical trial, some women said they would not participate because they were currently in
treatment, thus it was unclear whether they would pursue a clinical trial if they were not in
treatment or were in treatment that failed to stabilize or diminish their cancer.
Early stage patients who were cured of ovarian cancer were amenable to considering
clinical trials, but no conclusion can be drawn for that small subset of three early stage (I/II)
patients who consented to this study. Women with early and later stage ovarian cancer,
however, all stated a desire for information on clinical trials, and all stated that their family
members would support them if they participated in a clinical trial. Women indicated that they
hear about and discuss clinical trials mostly with their physician; for many physicians, however,
including some who are affiliated with institutions that offer clinical trials, clinical studies are not
a priority. Women are not always aware that recurrent cancer is terminal, or that the “gold
standard” is not synonymous with a cure.
Research Question 2. The data suggests that discussion with the provider of care, to
some extent the existence of patient-accessible clinical trial literature in the practice, knowledge
that health insurance covers standard of care costs, and the provider offering clinical trials are
facilitators for participation. Absence of those factors thus constitutes a barrier.
All women who participated in the study said they want more information about clinical
trials and that their families would support them if they participated in trials. Barriers are thus the
absence of discussion with providers, having a provider who does not offer on-site clinical trials,
and not knowing that one’s medical coverage will pay for the standard-of-care costs in a clinical
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trial, or that the Affordable Care Act stipulates that clinical trial costs must be covered. Women
believe that trials should be a final option after treatment fails, which is a significant barrier to
enrollment because they will likely fail to meet the inclusion criteria on number of prior
treatments that are allowed. Travel and extra visits were not a barrier to any of the women who
were surveyed.
Practice Nurses
Research Question 1. As previously explained, the small sample of nurses (7) was not
conducive to yielding a combination of conditions with coverage and consistency of 1.0. The
highest coverage and consistency were 0.8, for the impact of having a practice team plan
related to enrolling women with ovarian cancer in clinical trials, resulting in nurses feeling
informed and comfortable with questions women might ask about trials. Numerous combinations
of conditions were tried, and nothing else resulted in coverage and consistency that exceeded
0.75.
Research Question 2. More clinical-trial enrolling-referring nurses have a practice team
plan (67% versus 25%), suggesting that having a plan is a facilitator and not having one is a
barrier. Additional facilitators are recognition that health insurance covers standard of care
costs, and that the ACA supports clinical trial costs. While not quite reaching a 20% difference,
the perception that clinical trials should be the last resort after the standard of care has failed is
likely impeding eligibility because of limits on maximum prior regimens as well as having poor
ECOG scores associated with complications of advanced disease. The belief that women
should be informed about clinical trials as early as possible after diagnosis is a facilitator;
absence of that belief is thus a barrier to enrollment. The fact that women bring up the
discussion about clinical trials to enrollers may be related to the population that seeks care at
facilities that offer clinical trials; regardless, it suggests that women would do well to ask the
question, which, if no trials are offered on site, may result in a referral. Table 4.18 in Chapter
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Four suggests that practice resources could be used to improve knowledge and comfort levels
among all nurses.
Additional barriers stated by at least one nurse are feeling uninformed and
uncomfortable with questions, lacking resources for patients in the practice or nursing education
focused on ovarian cancer clinical trials. Barriers in the inner setting are failing to refer women
to sites with trials, and low levels of nurses initiating discussion about trials. Nurses, like
patients, are not always aware that health insurance covers standard costs of care for trial
participants, or that the Affordable Care Act stipulates that clinical trial costs must be covered.
Some nurses fail to see the benefit of early education and pursuit of ovarian cancer clinical
trials, believing they are a last resort after all treatments fail. The lack of trials having priority
status, as well as no incentives for trial enrollment, is an additional practice barrier to enrollment.
Challenges
The original intention for this study was to find at least twenty unique referring practice
sites and compare survey responses for the theoretical domains between the woman with
ovarian cancer and the referring practice nurse. The TCC search yielded only twenty referring
practices, and most of those practices were transformed in the last few years by industry
dynamics that led to the purchase of multiple practice sites by Florida Hospitals. Thus
independent practitioners became part of a large system in which physicians rotate to various
sites within one hospital system. It was thus impossible to match patients with referring
physicians and practice nurses.
The low response rate for practice nurses was unanticipated. A meta-analysis by Cho
and colleagues sought to clarify effective strategies for improving response, such as mode of
data collection, incentives, and number of follow-up attempts, all of which were found to be
significantly related to response rates of physicians and nurses. which have declined steadily
between 1958 (about 80%) to 2012 (about 40%) ({{Cho, Johnson, & Vangeest, 2013). The Cho
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team found that the online survey mode had the lowest rate of response (38%), compared to
mailed surveys (57%) and mixed types (49%), the last referring to blending fax and email with
mailing options for greater flexibility. The factors believed to diminish online survey response are
mistrust of the internet and regulations by gatekeepers. Personalization was cited as another
important element for improving response.
For invitations to take the survey, only physician names, not the names of their nurses,
were available, thus envelopes were addressed to the primary nurse for Dr. “Doe,” followed by
the practice address. The lack of personalization likely left the decision to deliver the letter up to
a gatekeeper, who may or may not have opened and delivered the letter. Lack of names greatly
complicated follow-up contacts; telephone calls, for example, requested the name of the nurse
for Dr. Doe, which brought the immediate response of Are you a patient? No, was my response,
but I am a nurse who needs to speak to her about clinical information, which sometimes got me
to the nurse’s voice mail, the next barrier, because nurses are extremely busy with patients.
Honesty with a particular gatekeeper precipitated her statement that all surveys must be
approved by the business office prior to being taken, and that the approval process would likely
take months. The alternate plan, attempting to engage nurses through a nursing professor in the
College of Nursing at the University of South Florida (USF) yielded three surveys. The next plan
was to place an invitation to take the survey in the USF College of Nursing newsletter, which
added one completed survey.
Strengths and Limitations
One strength of this study, on the patient side, is that the analysis focused only on women with
ovarian cancer and their behaviors, intentions, knowledge, beliefs, and attitudes related to
clinical trials, rather than on a blend of men and women with various cancers at various stages.
A weakness, however, lies in the fact that most women were patients at Moffitt Cancer Center,
where clinical research is part of the institution’s tripartite mission of combining clinical care,
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academic medicine, and translational research. The women who are treated at Moffitt Cancer
Center thus may be more aware of and informed about clinical research and may have a
physician who is a principle investigator. It should be pointed out, however, that not all
gynecologic oncologists at Moffitt Cancer Center are actively engaged in clinical trials.
The original intention was to find 20 women with ovarian cancer who had been referred
by 20 different practices, then survey a primary nurse for each of those practices. Chart reviews
followed by a search for practice locations did not yield 20 unique referring sites, partly because
some physicians had relocated and practice mergers under one large system had occurred,
whereby that physician now rotated through multiple sites. The inclusion of both medical
oncologists and gynecologic oncologists was necessary, however, because many women with
ovarian cancer opt to have adjuvant chemotherapy close to home, administered by a medical
oncologist. The low number of gynecologic oncologists compared to medical oncologists would
have made it difficult or impossible to find 20 unique practices. The goal was to determine
clinical trial enrollments and/or referrals in the 20 unique practices—that number of gynecologic
oncology practices does not exist. Gynecologic oncologists perform surgery and adjuvant
chemotherapy and generally have an assigned primary nurse; medical oncologists provide
chemotherapy but not surgery, and they do not have one dedicated nurse, making it difficult to
connect with medical oncology nurses without having a name. The lack of personalization, e.g.,
addressing the invitation letter to the “Primary Nurse of Doctor Doe,” likely had a lot to do with
the low response rate for nurses. While it would have been possible to recruit more nurses from
Moffitt Cancer Center, the purpose was to recruit nurses from external sites, and not have an
imbalance or overrepresent a facility that does offer clinical trials and has made clinical research
part of its culture.
The Total Cancer Care (TCC) data request had a small yield, omitting a number of
patients still living and with a history of care at Moffitt Cancer Center that exceeds three years,
which is a question that the investigator, having no hands-on knowledge of how various data
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bases are connected and manipulated, cannot answer. In the interest of protecting the privacy
of those who have consented to provide and store biospecimens and clinical data via Moffitt’s
TCC protocol, TCC, appropriately, is a “closed” system accessible only to honest brokers, thus
the process of pulling and merging data is confidential. Fortunately, there were several women
known to the investigator through their participation in other studies, and they were contacted
and agreed to participate in this study.
The dichotomous survey data, indicating presence or absence of a condition of interest,
led to why questions that could have best been clarified by follow-up interviews of women with
ovarian cancer as well as nurses. With only seven nurses completing surveys, it may have been
even more challenging to get them to agree to be interviewed. A subsequent study of this nature
should definitely include interviews to better inform the researcher on other conditions that
influenced the presence or absence of a condition. Interviews of nurses and patients would
have helped clarify the discrepancy between nurses’ knowledge and support of sharing
information about clinical trials early in the treatment continuum, and patients still embracing the
notion that trials should be considered only as a last resort
Recommendations
Future studies should follow up the survey with interviews of the populations of interest to
determine additional factors that influenced the presence or absence of a particular condition.
Research should focus on nurses’ perceptions of the value of research in the practice setting as
well as their knowledge, beliefs, and behaviors associated with cancer clinical trials. Nursing
education should enlighten nurses on the types and dimensions of research, including practice
patterns, behavioral, clinical, and translational science, and their value and contribution to
improved quality, satisfaction, and outcomes. This study could be applied to other cancers as
well, whether they are rare or more common, and especially where there is a need to define
barriers and facilitators to inform needed interventions to accelerate research. A pilot
90

intervention that involves multiple institutions and is comprised of the following components
within the Consolidated Framework for Implementation Research (CFIR) should be undertaken
(see Figure 5.2). Information and education should target all levels of the framework.

Legend: Green = All findings combined
Figure 5.2. Translating Findings into an Intervention as it Could Occur within the Consolidated
Framework for Implementation Research (CFIR)

Outer Setting
Provider and patient knowledge deficits exist with regard to insurance coverage of standof-care costs in clinical trials as well as ACA coverage requirements for clinical trial participants.
Helpful trial-matching tools are available and underused, and practice networks need to be
expanded by engaging larger numbers through the use of incentive-based partnerships. In the
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outer setting, multimedia education within each provider team member’s specialty organization
could focus on deficits in awareness, knowledge, and interpersonal communication skills.
Multimedia education could also be more fully integrated and made available to women with
ovarian cancer through voluntary health agencies such as the Ovarian Cancer National Alliance
and OCNA and the National Ovarian Cancer Coalition (NOCC), among others, as well as within
provider environments. Circumvention of practice barriers may require more overt connections
and education from pharmaceutical companies to lay consumers, raising awareness so that
patients ask more questions and become more proactive seekers of cutting-edge therapies.
Pharmaceutical connections with mass media and advocacy groups may accelerate enrollments
and help solve the problem of trials limited by biomarker requirements or low incidence that are
struggling to accrue adequate numbers of participants. Further, trial sponsors could create
incentives, such as a referral fee, to encourage inter-institution collaboration to increase clinical
trial enrollment. Non-monetary incentives might include benefits of partnerships that add an
academic and/or research recognition component and the assurance that the patient will be
referred back to the referring physician after the trial.
Inner Setting
All women with ovarian cancer expressed a desire for information on clinical trials, and
all but one expressed that she is comfortable asking for information. Providers need to share
information on clinical trials along with resources early in the treatment continuum, because
many women, and some providers, are misinformed about waiting until the “gold standard” fails
to consider clinical trials. Admittedly, changing practice culture is a huge undertaking that
requires multidisciplinary and multi-institutional collaboration with partnerships and commitment
at many levels. Determining the best ways to drive the change is an ambitious project that
requires additional study and input from many leaders across industries and nonprofit settings.
Networks must be created, resources shared, and technology amped up to bridge distance.
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Compromise might involve infrequent travel by a patient to a central institution for baseline
genomic testing and regulatory startup, with delivery of the intervention, surveillance, and data
monitoring at a satellite site that shares data with the central institution. Today’s trials include
biomarker-based agents as well as early trials to extend remission. Waiting until all treatments
fail will reduce the likelihood of fulfilling eligibility criteria for number of prior treatments. Innersetting education in the practice setting for all providers and patients is needed in multiple
formats such as dialog, print, and video. All practice participants need to be aware of the NCCN
guideline that women with recurrent or advanced ovarian cancer should include the option of a
clinical trial in addition to the standard of care.
Process
A protocol for a uniform pathway process, from diagnosis throughout the treatment
continuum, needs to be created to guide providers in starting and sustaining informed patientcentered dialog on ovarian cancer clinical trial opportunities, procedures, and resources. The
process must employ metrics that measure provider adherence, patient satisfaction, adherence,
and outcomes such as the number of enrollments and the impact of enrollment on longevity and
quality of life.
Adapted Intervention
With no intervention, as the situation currently exists, enrollments are low and often
nonexistent in un-networked practices that lack the necessary infrastructure for offering clinical
trials. With a well-defined, protocol-driven process, fully engaged collaborative patient-centered
practice networks, trial-referral incentives, retention of patients by referring physicians, and
better informed nurses and patients, enrollment in ovarian cancer clinical trials would likely
increase.
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Conclusion
This multiple case study, by surveying nurses and women with ovarian cancer, identified
deficits within specific populations that interact with regularity for the purpose of ovarian cancer
diagnostics, treatment, and quality of life management throughout the care continuum. The
standard of care can improve only via the clinical trial process, and yet the rarity of ovarian
cancer makes adequate accrual numbers for statistical power difficult to achieve. It is thus
especially important that regional, statewide, and national accrual-promoting network strategies
be developed and shared to increase opportunities for women with advanced disease to enroll
in clinical trials. Clinical trials are an underutilized priority for improving the standard of care and
reducing the high rate of morbidity and mortality associated with ovarian cancer. The data show
deficits and needs within two key interrelated populations: medical oncology practice nurses and
women with ovarian cancer. Opportunities exist within each level of the Consolidated
Framework for Implementation Research (CFIR); the findings can be related to each CFIR level
to establish an interventional protocol to increase timely clinical trial enrollment by women with
ovarian cancer. The next step is to pilot targeted interventions and disseminate findings. Results
will be published in nursing and women’s health journals, and will be shared with appropriate
advocacy groups, such as the Ovarian Cancer Research Foundation. The long-term goal is the
establishment of a successful model for increased timely enrollment in ovarian cancer clinical
trials, reduced morbidity and mortality, and improved quality of life.
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